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ABSTRACT
ADAM10 dysregulates Notch signaling in favor of myeloid derived suppressor cell
accumulation (MDSC) that deferentially modulates the host response depending on
immune stimuli and interaction with mast cells.
By Sheinei J. Saleem, PhD
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2013
Director: Daniel H. Conrad, Professor, Department of Microbiology and Immunology
Although the physiological consequences of Notch signaling in hematopoiesis
have been extensively studied, the differential effects of individual notch cleavage
products remain to be elucidated. Given that a disintegrin and metalloproteinase 10
(ADAM10) is a critical regulator of Notch and that its deletion is embryonically lethal,
we generated transgenic mice that overexpress ADAM10 at early stages of lymphoid and
myeloid development (A10Tg). ADAM10 transgene expression alters hematopoiesis
post-hematopoietic Lineage-Sca-1+c-kit+ (LSK) subset differentiation but prior to lineage
commitment of progenitor populations. This results in delayed T cell development,
abrogated B2 cell development, and dramatic expansion of functionally active myeloid
derived suppressor cells (MDSCs) in A10Tg mice. Given ADAM10’s role in Notch
signaling, we hypothesized that the observed hematopoietic alterations may be a
consequence of perturbed Notch signaling. In fact, blockade of ADAM10 (S2) rescues B
cell development and reduces myeloid cells in A10Tg LSKs. Inhibition of γ-secretase
(S3) in wild type (WT) LSKs results in enhanced myelopoiesis, mimicking the

xx

phenotype of A10Tg mice. Collectively, these findings indicate that the differential
cleavage of Notch into S2 and S3 products regulated by ADAM10 is critical for
hematopoietic cell-fate determination.
Albeit arising in a tumor-free host, A10Tg MDSCs are functionally and
phenotypically analogous to tumor-derived MDSCs. A10Tg MDSCs inhibit T cell
activation in vitro, and inhibit adoptive immunotherapy (AIT) of metastatic melanoma in
vivo, which can be reversed with MDSC depletion. Intriguingly, A10Tg mice are
resistant to parasitic infection upon inoculation of Nippostrongylus brasiliensis.
However, depletion of MDSCs abrogates this response, while adoptive transfer (AT) of
MDSCs into WT mice increases their resistance. This polarized activity of MDSCs is
heavily dependent upon interaction with mast cells (MCs). In fact, B16 melanoma cells
metastasize more rapidly in WT mice infused with MDSCs when compared to MCdeficient mice (Kit

Wsh/Wsh

), with or without MDSC AT. Parallel to B16 progression, the

ability of MDSCs to promote anti-Nb immunity is significantly diminished in MCdeficient (Kit Wsh/Wsh) mice even with MDSC AT. This augmentation of MDSC activity in
the presence of MCs is further corroborated by in vitro co-culture assays that
demonstrate a synergistic increase in cytokine production. Furthermore, MDSCs
preferentially migrate to the liver in a MC-dependent manner. This interaction is
mediated by MC-released histamine. In fact, MDSCs express histamine receptors (HR)
and histamine induces MDSC survival, proliferation, and activation. We demonstrate that
MDSC activity is abrogated with histamine blockade. Moreover, in humans, allergic
patients present with an increase in MDSC population, and MDSCs purified from a stage

xxi

I breast cancer patient exhibit increased survival in the presence of histamine. Taken
together, our studies indicate that MCs and MC-released histamine are critical for the
observed functional duality of MDSCs, ranging from immunosuppressive to
immunosupportive, depending on the disease state.

INTRODUCTION
I. ADAM10 is critical for hematopoietic cell differentiation.
Disintegrin and metalloproteinases (ADAMs) regulate cell signaling pathways by
cleaving the extracellular domains of membrane-bound receptors and ligands.
Consequently, these proteins serve as initiators for signaling pathways that require
regulated intramembrane proteolysis (RIP) of receptor:ligand complexes. The shedding
of membrane anchored proteins releases soluble fragments into the extracellular milieu
that can subsequently modulate signaling events. Although ectodomain shedding is
thought to occur constitutively, RIP requires the binding of ligands expressed on adjacent
cells. Numerous receptors including Notch undergo regulated proteolysis of the receptor:
ligand complex to release their intracellular domains (ICD), that subsequently
translocates to the nucleus and alters gene expression. Mutations in the negative
regulatory region (NRR) of ADAM substrates can cause ligand-independent
intramembrane proteolysis, resulting in excessive ICD signaling and numerous
pathological conditions(1-5).
The prototypical ADAM contains an inhibitory pro-domain, a highly conserved
metalloprotease domain, a disintegrin domain conferring substrate specificity, a cysteinerich region, a transmembrane portion, and a cytoplasmic tail capable of binding SH3
domains(6, 7). Among the 38 ADAMs identified to date, the most studied are ADAMs 8,
9, 10, 12, 15, 17, and 33, that contain the conserved zinc-binding consensus motif which
confers proteolytic activity to the protease domain. Within this subset, ADAM10 has
emerged as an important mediator of ectodomain shedding and RIP of multiple substrates
1	
  

including epidermal growth factor (EGF), Fas-ligand, CD23, and most notably Notch.
This proteolytic processing is critical for appropriate cellular processes and its
dysregulation results in the pathogenesis of multiple disease states, including
Alzheimer’s, cancer, and inflammation. Thus, there is growing interest in elucidating
ADAM10 as well as its inhibition for pharmacologic treatment. However, determination
of the physiologic consequences of ADAM10-mediated cleavage events has been limited
by lethality of ADAM10-null murine embryos. These same studies highlight the
important role of ADAM10 in hematopoietic cell development mediated via regulation
of Notch signaling(8, 9).
Many studies have indicated the importance of Notch signaling in lymphocyte
development. The Notch signaling pathway is highly conserved, consisting of four
families of receptors (Notch1-4) that interact with ligands (Jagged and Delta) expressed
by neighboring cells(10-12). Following ribosomal synthesis, the Notch receptor
undergoes a furin-mediated maturation at site 1 (S1) in the Golgi apparatus prior to
trafficking to the cell surface. At the surface, Notch is expressed as an integral membrane
protein, consisting of both extracellular (NEXT) and intracellular domains (NICD). Once
engaged with its ligand, the extracellular domain undergoes an ADAM10-mediated
cleavage at site 2 (S2). This event generates a substrate for the γ-secretase complex to
perform a final cleavage of Notch at site 3 (S3), releasing the transcriptionally active
NICD(3). Several studies have reported the accumulation of intact receptor and the S2
product as a result of ADAM10 and γ-secretase blockade, respectively(2, 4)CITATION_IS_EMPTY.

Although inhibition of both enzymes prevents NICD activation, the
2	
  

consequences of accumulation of these different cleaved products on hematopoiesis
remains to be determined.
A. Discovery of ADAM10 as main sheddase of Notch1.
ADAM10 has been characterized after extensive study of its drosophila homolog,
Kuzbanian (kuz). Rooke et al. initially identified Kuz in 1996 from the generation of kuz
deficient embryos. The authors revealed its essential role in lateral inhibition required for
development of peripheral and central nervous systems. Cloning and sequencing analysis
of kuz demonstrated the presence of disintegrin and metalloproteinase domains that
exhibited a 43% amino acid identity to its mammalian homolog, bovine metalloprotease
(BMP)(1-6). This was isolated from myelin and shown to cleave myelin basic protein.
For this reason, BMP, which was later named ADAM10, was initially well characterized
in the cleavage of amyloid plaque proteins and Alzheimer’s disease(7-9). Later, by
overexpressing dominate negative (DN) mutants of kuz in drosophila and Xenopus, Pan
et al. demonstrated the requirement for kuz to initiate RIP of Notch (10-12). The
contribution of ADAM10 is further supported by the generation of ADAM10-deficient
embryos and conditional knockout mice. These studies, which mostly focused on Notch
1, indicated impaired development in the absence of ADAM10 and consequent impaired
Notch signaling(6,13-16). As mentioned earlier, ADAM10-medaited S2 cleavage
generates a substrate for γ-secretase complexes to perform the S3 cleavage of the
receptor, releasing NICD that subsequently translocates to the nucleus and induces
transcriptional activation (Fig. 1). The NICD complexes with the transcription factor
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RBP-Jκ, and induces transcription of Notch target genes, including Hairy enhancer of
split (Hes1), Hes5, and Deltex-1(4,9).
Although ADAM10 is now considered the main sheddase of the Notch1
Receptor, it was initially considered to be highly controversial(3-5,12). Several groups
reported that ADAM17 (TNF-α converting enzyme, TACE) conducted the S2 cleavage
of Notch1 receptor(3,5,13,15,16). In fact, loading cell membrane fragments from Notchtransfected HeLa cells onto RED-TSK columns resulted in co-elution of Notch receptor
cleavage products with ADAM17, rather than ADAM10. Moreover, an in vitro
monocytic cell differentiation experiment demonstrated ADAM17’s ability to cleave
Notch1 and direct Notch-dependent monocyte differentiation(5). Thus, ADAM17 is often
referenced in the literature as the relevant proteinase that initiates Notch signaling.
Although these findings were in direct contrast to studies of kuz in drosophila, the
authors could not rule out ADAM10-directed Notch cleavage. They suggest that
ADAM10 and ADAM17 may be functionally redundant in vivo. It is plausible that in the
absence of ADAM17, ADAM10 can serve a compensatory role and vice versa. In
support of this, several studies have demonstrated that ADAM10 can cleave many
ADAM17 substrates from ADAM17-/- murine embryonic fibroblasts (MEFs)(17).
However, the exclusive contribution of ADAM10 in Notch activation became more
acceptable following the generation of ADAM10-deficient mouse embryos that
displayed many features observed in nonviable Notch1-/- embryos(12,18). In contrast,
embryonic loss of ADAM17 did not result in a Notch1-/- phenotype(19). Following these
observations, two groups utilizing ADAM10-/- MEFs reported that while multiple
4	
  

proteases can perform ligand-independent proteolysis of Notch1, ADAM10 is required
for ligand-dependent cleavage(16,20). Thus, ADAM10 may play a more critical role in
Notch signaling than earlier in vitro studies predicted. Additional studies are required to
further elucidate ADAM10-mediated cleavage events in hematopoietic development but
are limited by in utero lethality of ADAM10-null embryos.
B. ADAM10 in lymphocyte development.
Notch1 signaling is essential for the development of thymocyte precursors. This
is best illustrated by the presence of thymic B cells in mice that lack Notch1 expression
in common lymphoid progenitors (CLPs)(21). Additionally, enforced Notch1 signaling
in BM progenitors expressing the constitutively active NICD promotes T cell
development(22). In fact, human mutations in the NRR surrounding the S2 cleavage site
of Notch1 results in ligand-independent proteolysis and excessive Notch1 activation,
ultimately causing T cell acute lymphocytic leukemia (T-ALL). This mutation accounts
for approximately 50 percent of all T-ALL cases(4). Multiple groups have reported
effective use of γ-secretase inhibitors (GSIs) in limiting T cell development in vitro and
in mouse models of T-ALL(23,24). However, GSIs cause gastrointestinal disease and
must be coupled with potent anti-inflammatory drugs, such as dexamethasone, in T-ALL
mouse models(23). Thus, there has been great interest in elucidating the role of ADAMs
in Notch1-mediated thymocyte development. Manilay et al. circumvented the limitation
of ADAM10-/- embryo lethality by generating transgenic mice that overexpress the
dominant negative form of ADAM10 (dnKuz) under control of the T cell-specific
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promoter, lck(25). dnKuz expression caused a partial block in thymocyte development
between the double negative (DN) and double positive (DP) stages as indicated by
decreased TCRβ expression and premature down-regulation of CD25. While these
findings were also observed in Notch1-deficient thymocytes, there were discrete
differences in thymocyte development and gene expression between dnKuz and Notch1
deficient mice(26). dnKuz mice have reduced levels of DN thymocytes and γδ T cells,
whereas conditional Notch1-deficient mice do not, suggesting that ADAM10 may
regulate early thymocyte development by processing other substrates in addition to
Notch1. Notch ligand, DLL-1, rescued thymocyte development in dnKuz mice in a noncell autonomous manner, indicating that ADAM10 may regulate thymocyte development
by processing DLL-1 expressed on adjacent cells. This is supported by studies of MEFs
in which ADAM10 was demonstrated to be the main sheddase of DLL-1(27). Further
examination of ADAM10’s role in thymocyte development awaited the production of
ADAM10-floxed mice, which has resulted in significant progress toward elucidating the
physiologic impacts of ADAM10-mediated cleavage events. By utilizing lck-cre
transgenic mice, Tian et al. reported impaired development and suppressed Notch1
signaling in ADAM10-deficient thymocytes(14). ADAM10-deficient thymocyte
development resembled that of dnKuz and lck-directed Notch1-deficient mice. The
authors further demonstrated that production of the NICD was not detectable in
ADAM10-deficient thymocytes.
B2 lymphocytes, which comprise the majority of circulating B cells, develop
from CLPs and differentiate into pro-, then pre-, and ultimately immature B cells prior to
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exiting the BM. Given that the Notch1 cleavage site recognized by ADAMs is not
present in murine Notch2, and that B cells express Notch2 rather than Notch1, ADAM10
has not been attributed to B2 B cell development(5,13,28-31). Just as Notch signaling
promotes CLP commitment to the T cell lineage, it prevents B lineage fate. Thus,
multiple studies have demonstrated that enforced expression of active NICD in BM
progenitors completely abrogates B2 cell development(22,31). Following exit from the
BM, B2 cells enter a transitional stage and undergo further maturation in the spleen,
where the majority differentiate into follicular B cells, while a subset develop into cells
of the marginal zone B (MZB) cell lineage, including pre-MZBs and MZB cells. By
generating B-cell specific Notch2 knockout mice, Saito et al. demonstrated that Notch2
signaling is required for development of the MZB cell lineage, which initiates immune
responses to blood-borne infections and transports antigen into the spleen
follicles(13,32). Moreover, by deleting ADAM10 in a mature B cell-specific manner
with CD19-cre knockin mice, Gibb et al. also demonstrated an absolute requirement for
ADAM10 in MZB development(33). Analysis of Notch target gene expression revealed a
dramatic defect in Notch2 signaling. Furthermore, in contrast to WT B cells, ADAM10null cells were completely unresponsive to DLL-1-induced Notch stimulation. These
findings not only revealed the importance of ADAM10 in B cell development, but also
demonstrated that ADAM10 is responsible for activating RIP-mediated signaling through
Notch2. In contrast to reports of ADAM10 deletion in thymocytes, deletion in mature B
cells did not result in any compensatory Notch2 cleavage by other proteases, including
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ADAM17. Thus, ADAM10 may be the only protease that can recognize the Notch2
cleavage site, which is distinct from the Notch1 site(5).
C. ADAM10 in myeloid cell development.
In the classical model of hematopoiesis, hematopoietic stem cells (HSCs)
differentiate to yield common myeloid progenitors (CMPs) and CLPs(34). CMPs
undergo further differentiation into mature myeloid cells, including the recently
identified myeloid-derived suppressor cells (MDSCs). Due to the deleterious role of
these suppressor cells in anti-tumor responses, myeloid differentiation has been the
subject of many recent investigations(35). As discussed further below, numerous
hematopoietic pathways, including Notch signaling, have been implicated in MDSC
development but remain controversial. Several investigators have reported that
alterations

in

Notch

signaling

have

minimal

effects

on

the

myeloid

compartment(22,36,37).Yet, Kawamata et al. reported that constitutive Notch signaling
promotes myeloid differentiation in a non-cell autonomous manner(31).This is supported
by a report of abrogated B cell and myeloid cell development in mice deficient in
downstream targets of Notch(38). However, other studies have indicated that Notch
signaling inhibits myeloid differentiation(39,40). Qyang et al. demonstrated that
blockade of Notch signaling at the γ-secretase cleavage site induces myeloid
accumulation(40).
Many of these alterations were observed in mice with altered lymphocyte
development. This suggests that ADAM10 directed Notch signaling may modulate the
differentiation pathway of CLPs and CMPs from a common upstream progenitor. Two
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groups have recently described common myelo-lymphoid progenitors (CMLPs) that are
indistinguishable from HSCs(34,41). Although these multipotent cells often commit to
the B or T cell lineage, they retain the potential for myeloid development. Therefore,
alterations in Notch signaling during lymphocyte development could also affect
myelopoiesis. Collectively, these findings indicate that myeloid differentiation may be
regulated by the signal strength and temporal stage of Notch signaling. Therefore,
examination of other Notch regulators, including ADAM10, could clarify the role of
Notch signaling in myeloid differentiation.
II. Development of myeloid derived suppressor cells (MDSCs).
As mentioned earlier, hematopoiesis is the hierarchal differentiation of
multipotent progenitors into mature blood cells of various lineages and functions. The
BM microenvironment provides a complex network of cytokines, transcription factors,
and intercellular signaling pathways, to tightly regulate the progressive lineage
commitment of hematopoietic stem cells(42). HSCs themselves are characterized by a
lack of lineage markers and by expression of the receptor tyrosine kinase (RTK) c-kit and
the surface protein Sca-1, together termed Lin-Sca-1+c-kit+ (LSK)(43). The expression of
Flt3 RTK and CD34 further subdivide the LSK compartment into self-renewing long and
short-term HSC populations as well as a multipotent progenitor (MPP) population. This
hierarchy descends deeper into lymphoid and myeloid compartments where the
progenitors are again subdivided into three distinct populations based upon CD34 and
low affinity IgG Fc receptors (FcgRII/RIII). These include CD34+FcgRII/IIIlo Common
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Myeloid Progenitors (CMP), CD34+FcgRII/IIIhi Granulocyte-Macrophage Progenitors
(GMP), and CD34-FcgRII/IIIlo Megakaryocyte-Erythroid Progenitors (MEP)(44).
In the classical dichotomous model of differentiation, MPPs give rise to either
lineage restricted common myelo-erythroid progenitors (CMEP) or common lymphoid
progenitors (CLPs)(45). This process is dependent upon the expression of three proteins:
c-kit, the IL-7 receptor and recombination activation gene 1 (RAG1)(46). The relative
expression of these species act as a ‘switch’ that determines the ultimate hematopoietic
endpoint. While RAG1 and IL-7R expressing CLPs give rise to T and B lymphocytes, cKit+ CMEPs are observed to generate myeloid and erythroid cells(47,48). This classical
model has been recently challenged by the idea that lineage restriction is not necessarily
permanent. Several independent observations indicate that early thymocyte and B cell
progenitors retain myeloid potential, leading to an alternative, ‘myeloid-based’
mechanism of hematopoiesis(34,41). CMLPs that are phenotypically indistinguishable
from LSKs have been observed, and these cells give rise to either B cells, T cells, or
myeloid cells. The myeloid-based mechanism excludes the existence of CLPs, stating
that differentiation occurs from these CMLP and CMEP progenitors(49). This suggests
that, although committed toward T or B lineage, progenitor cells retain the potential
towards myeloid lineage. The existence of progenitor myeloid, B and T (p-MBT) cells
which are committed B or T cells, yet retain the ability to revert back to myeloid cells
further support this possibility(50). Additionally, the observation of several leukemic
disease states containing cells of both myeloid and lymphoid origin indicate that a close
relationship exists between p-MTB progenitors(34). This process is heavily influenced
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by the microvasculature in terms of cytokines and signaling pathways it can provide to a
developing HSC. Therefore, the unique cytokine profiles in any given pathologic state
can also heavily impact hematopoiesis and thus the subsequent immune response.
In response to physiological insult, such as that generated by a pathogenic
organism, the host enters a state of ‘emergency’ hematopoiesis characterized by
increased recruitment of myeloid lineage cells such as neutrophils and macrophages(51).
However, during chronic inflammatory stimuli such as in cancer progression, severe
hematopoietic dysregulation can occur at the CMLP or GMP/CMP stages of
differentiation(52). This results in the premature BM recruitment of a heterogeneous
population of mononuclear (CD11b+Gr-1intLy6G- Ly6C+) and polymorphonuclear
(CD11b+Gr-1highLy6G+ Ly6C-) MDSCs(35). As discussed below, MDSCs accumulate in
response to a variety of cytokine and transcription factor alterations unique to a given
disease-state such as cancer, the natural aging process, solid organ transplantation,
parasitic infections, sepsis, autoimmune disease, trauma, and burns(53-56). The
phenotypic and functional characteristics of MDSCs strongly underscore their myeloid
origin. Common cytokines involved in myeloid development have been implicated in the
induction of MDSCs. These factors include macrophage-colony stimulating factor (MCSF), granulocyte-macrophage colony stimulating factor (GM-CSF), Interleukin-6 (IL6), vascular endothelia growth factor (VEGF), and granulocyte-colony stimulating factor
(G-CSF). Several transcription factors involved in myelopoiesis such as interferonregulatory factor 8 (IRF-8), CAAT/enhancer binding protein-beta (C/EBP-β), and PU.1
have also been demonstrated to regulate MDSC development(57). In addition to myeloid
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differentiation antigen Gr-1 and CD11b, MDSCs also express various other markers that
are traditionally used to define myeloid cells such as CX3CR1, CCR2, CXCL10, CD206,
and IL-1B. In fact, CD11b+Gr-1+CCR2+CX3CR1low MDSCs can be considered as
inflammatory monocytes and can differentiate into DC and macrophages under
appropriate stimuli. The expression of IL-4Ra further supports the differentiation of
MDSCs into monocytic (IL-4Ra+) and polymorphonuclear cells (IL-4Ra-) with the
monocytic fraction expressing a more substantial immunosuppressive character due to its
ability to secrete IL-13 and IFN-γ(58,59). Recent investigations demonstrate that, at the
tumor site, MDSCs bear several classically activated (M1) and alternatively activated
(M2) macrophage phenotypic and functional characteristics(59). MDSCs express IL-1B,
TNF-α, CXCL10, and inducible nitric oxide synthase (iNOS) that is characteristic to M1
macrophages as well as CD206, and arginase I (Arg I), which are M2 specific. Since
MDSC development and proliferation occur in an asynchronous manner along the
differentiation of CMPs and GMPs toward mature myeloid cells, it is not surprising that
they retain a ‘fluid’ spectrum of myeloid cell characteristics.
Despite the ambiguity surrounding their origin, MDSCs are most prominently
recognized for their role in the anti-tumor immune response. MDSCs exert their proneoplastic effects through the release of small soluble oxidizers, the impairment of Tcell-antigen recognition, and the depletion of essential amino acids from the local
extracellular environment, all ultimately leading to suppression of T cell responses(6064). Additionally, through overproduction of cytokines and angiogenic factors, MDSCs
shift immune regulation to a state favoring both tumor escape and proliferation(64).
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Although the biological and functional properties of myeloid derived suppressor cells
have been well characterized and described elsewhere, the mechanism(s) of their
development remains controversial(35,65,66). This review outlines the role of commonly
implicated cytokines and cytokine-mediated transcription factors in MDSC expansion.
Furthermore, several controversial mechanisms of MDSC mobilization are discussed,
including the recent observation of MDSC expansion induced by Notch-mediated
hematopoietic dysregulation.
A. Cytokine and cytokine-induced transcriptional regulation of MDSC expansion.
A1. Interleukin-6. As mentioned earlier, emergency granulopoiesis is the natural
immune response to an infection, which results in the overproduction of myeloid cells.
Through differentiation, these myeloid cells afford increased populations of monocytes,
granulocytes, neutrophils, and more recently, MDSCs in the circulatory system to serve
as regulators of the immune response(67). Inflammatory cytokines play a critical role in
this process, particularly interleukin 6 (IL-6). IL-6 is a pleiotropic cytokine secreted by
numerous immune and non-immune cells. In a state of emergency granulopoiesis, IL-6
induces the production of acute phase proteins and antibodies by B lymphocytes, while
simultaneously mediating hematopoietic progenitor differentiation(68). One of the
multiple biological activities of IL-6 comes from its interaction with the CAAT/enhancer
binding protein-beta (C/EBP-β) protein, a transcription factor of the leucine zipper
family(69). C/EBP transcription factors regulate granulopoiesis; C/EBP-α is required in
steady-state granulopoiesis, while C/EBP-β is exploited as a mediator for emergency
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granulopoiesis. C/EBP-α is itself an activator for several requisite genes in myeloid
development, in particular the granulocyte-colony stimulating factor receptor (GCSFR)(70). In the absence of C/EBP-α, abnormal myeloid differentiation from CMP to
GMP has been reported(71). Although C/EBP-β has been observed during myeloid
differentiation, its abrogation does not result in abnormal granulopoiesis. Nonetheless,
C/EBP-β appears to specifically affect MDSC production, as myeloid precursors in
C/EBP-β-/- mice are unable to differentiate into MDSCs(72,73). Additional observations
suggest that the role of C/EBP-β extends beyond being requisite for MDSC development;
C/EBP-β itself may exert a pro-MDSC effect. In vitro experiments have indicated that
C/EBP-β promotes the generation of functionally active MDSCs in the presence of IL-6
and the granulocyte-monocyte colony stimulating factor (GM-CSF)(67). Furthermore,
using an in vivo murine model, upregulation of C/EBP-β has been shown to correlate
with an increase in the degree of immunosuppression induced by a growing
tumor(67,74). While not directly attributable to MDSC production, this observation is
consistent with the immune suppression expected from enhanced MDSC expansion.
In direct support of the myeloid-based model of differentiation, IL-6 acts on
lymphoid cells possessing myeloid potential, favoring myelopoiesis. The importance of
IL-6 is clearly underscored in transgenic mice containing a deletion of the 5’ inositol
phosphatase (SHIP) gene. This modification mimics a state of emergency granulopoiesis
with concomitant overproduction of IL-6(75). As a consequence, these mice
phenotypically exhibit severe splenomegaly due to the accumulation of functionally
active CD11b+Gr-1+ cells. Like tumor-derived MDSCs, these cells significantly impair
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priming of allogeneic T cell responses and render the animals less susceptible to Graft
versus Host Disease (GVHD)(76,77).
A2.GM-CSF. The granulocyte-macrophage colony stimulating factor (GM-CSF) is
recognized as a critical hematopoietic cytokine, mediating the differentiation of myeloid
progenitors

into

granulocytes,

eosinophils,

monocytes,

megakaryocytes,

and

erythrocytes(1). Remarkably, depending on the concentration of GM-CSF, this factor can
exert either a stimulatory or an inhibitory effect on the immune system. In low
concentrations, GM-CSF enhances antigen presentation by dendritic cells (DC) as well as
cytotoxic CD8+ and T helper CD4+ T cell responses(78). However, as the concentration
of GM-CSF is increased, downregulation of DC differentiation and induction of
CD11b+Gr-1+ MDSC accumulation can occur(79). Ultimately, this process results in a
state of severe immunosuppression, as observed in most cancers. The accumulation of
MDSCs is believed to be a specific consequence of GM-CSF’s ability to skew
hematopoiesis towards myeloid development. Several studies have reported GM-CSF
induced

myelopoiesis

that

is

consistent

with

the

myeloid-based

model

of

hematopoiesis(80-82). Transgenic expression of GM-CSFR in hematopoietic tissue
results in a preferential shift towards myeloid progenitors at the CMP, GMP and MEP
stages(83). Accordingly, these subpopulations favor myeloid development at the expense
of lymphoid committed progenitors, hence preventing subsequent lymphopoiesis(84).
This is further supported by the observation of myeloid development from committed
CLPs when the IL-2RB receptor is inserted into CLPs to upregulate GM-CSFR(85).
Accordingly, it is not unreasonable to believe that excessive GM-CSF production, as
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seen in conditions leading to MDSC accumulation, can skew CMLP and CMEP lineage
commitment towards dysregulated myelopoiesis.
A3. G-CSF. The granulocyte-colony stimulating factor (G-CSF) and its receptor
are critical regulators of steady state and emergency granulopoiesis. G-CSF promotes the
survival, mobilization, and proliferation of myeloid progenitor cells alongside neutrophil
differentiation. G-CSF likewise enhances myriad neutrophil functions including
phagocytosis, cytokine production, antibody-dependent cellular cytotoxicity, and
bactericidal activity(86,87). Mice deficient in G-CSF or G-CSFR suffer from neutropenia
and succumb to bacterial infections due to the decreased activity of resident
neutrophils(87). In vivo and in vitro administration of G-CSF reflects its
immunomodulatory effects. In the clinical setting, G-CSF is used to treat neutropenia
resulting from congenital pathologies or immunosuppressive therapy. However, a
fraction of patients receiving G-CSF have developed myeloproliferative disorders such as
acute myeloid leukemia (AML)(88). In addition, G-CSF administration can reduce DC
and cytotoxic T cell activity, and promote the induction of IL-10 producing myeloid
cells(79).
G-CSF mediated MDSC accumulation has been reported in both tumor models
and in vitro studies(55,64). This process is attributed to the interplay between G-CSF and
several cytokines and transcription factors known to induce MDSCs. In this case, the
relationship with other mediators is immediately apparent: the transcriptional initiation
site of G-CSF itself contains binding sites for both IL-6 and NFkB. While the role of IL6 was clearly outlined earlier, NFkB provides a second pathway by which MDSC
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accumulation may occur. In fact, MDSC accumulation has been observed in pathologies
during which NFkB is activated through toll-like receptor (TLR) mediated myeloid
differentiation primary response gene 88 (MyD88) signaling, including sepsis, trauma,
and particular microbial and viral infections(73,89). Moreover, other inflammatory
mediators implicated in MDSC expansion such as IL-1 and IL-17 also activate GCSF(90-94). Additionally, the G-CSF responsive genes, PU.1 and C/EBP-β are
positively correlated with MDSC upregulation(38,94).
Nonetheless, the primary consequences of G-CSF mediated myelopoiesis emerge
from activation of the G-CSF receptor (G-CSFR) in the BM. Following activation, GCSFR initiates signaling cascade through the Janus Kinase (Jak) / signal transducer and
activator of transcription (STAT) pathway(95). STAT proteins are latent cytoplasmic
transcription factors activated by a variety of hematopoietic and immune-mediated
cytokine receptors. The critical role STATs in hematopoiesis is illustrated by the close
association between lymphoproliferative and myeloproliferative disorders with
dysregulated STAT signaling(96). In hematopoietic tissue, G-CSFR is the main activator
of STAT3 and, to a lesser degree, STAT1 and 5(95). Phosphorylation of STAT3 is
markedly increased in tumor-derived MDSCs, and inhibition of STAT3 phosphorylation
in hematopoietic progenitors markedly diminishes MDSC expansion(97). Likewise, the
activity of STAT3 in myeloid progenitors prevents differentiation and induces immature
myeloid cell expansion(94). The downstream signaling partners of STAT3, in particular
S100A8 and S100A9 also modulate behavior in the myeloid compartment.
Overexpression of S100A9 results in an enhanced c-kit+ myeloid compartment in the
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BM(98). S100A9 acts in concert with S100A8 to inhibit DC differentiation and promote
MDSC expansion. Further MDSC-mediated immune suppression and survival is
mediated through STAT1 and STAT5 pathways(73). Given the wide range of G-CSF
activities in the BM, it is not surprising that G-CSF secretion by tumor cells and its in
vitro administration can skew hematopoiesis in favor of MDSCs.
A4. M-CSF. The macrophage-colony stimulating factor (M-CSF), also known as
CD115, is a critical regulator of monocytic development. M-CSF signals through its
corresponding tyrosine kinase receptor, which is widely expressed on the CMP and GMP
myeloid compartments(57). M-CSF serves a physiological role in the proliferation and
differentiation of monocytes, macrophages, and DCs. In genetically altered murine
models, the absence of M-CSF and / or its receptor induces a dramatic reduction of
peripheral monocyte populations that is only restored upon transgene expression of MCSF(99).
The M-CSFR promoter contains binding sites for several transcription factors
implicated in myeloid development, including PU.1, C/EBP-α, and C/EBP-β(100,101).
Furthermore, dimerization of the M-CSF receptor activates numerous downstream
pathways, including Stat1, the Ras/Raf/MEK/ Erk pathway, and the phospholipase Cγ
(PLCγ) pathway(102). These pathways exert manifold regulatory roles in cell-fate
determination. In particular, activation of protein kinase c (PKC) by PLCγ promotes
monocyte differentiation, while blockade of ERK signaling in vitro induces subsequent
abrogation of monocytic differentiation from FDC-P1 cells(103). Signaling through the
ERK pathway is necessary to modulate commitment of lymphoid-myeloid progenitor
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cells toward CMPs rather than CLPs. Accordingly, hematopoietic cells with myeloid and
lymphoid potential exhibit a high sensitivity to M-CSF and undergo differentiation
towards myeloid cells at high M-CSF concentrations(104). In fact, under high M-CSF
concentrations inhibit proper myeloid differentiation and promote the differentiation of
DCs into monocytes-like cells with macrophage like characteristics(105).
Several markers indicate that M-CSF exerts a prominent role in MDSCs-related
disease states. In particular, M-CSFR mRNA is induced in several pathological
conditions in which MDSCs have been implicated. Once recruited to the site of an
immune insult, macrophages initiate an autocrine loop of M-CSF production. This, in
turn, alters hematopoiesis and induces the recruitment MDSCs to the site of insult(106).
Furthermore, once recruited to the site, MDSCs perpetuate the loop by producing M-CSF
on-site(107). As a consequence, it is not surprising the MDSCs have been observed in
many infections and pathological conditions in which macrophage response is desirable.
In a second pathway, M-CSF is regulated by the transcription factor MafB to
restrict lineage commitment toward myelopoiesis(108). The relationship between MafB
and M-CSF is evident in murine models, in which the overexpression of MafB limits
myeloid differentiation. Conversely, a MafB deficiency in these models has been shown
to render myeloid progenitors more sensitive to M-CSF. As a consequence, increased
PU.1 activity is observed, shifting hematopoiesis toward myeloid development(109). In
addition, MafB is highly expressed in LT-HSCs and becomes downregulated during
intermediate stages of HSC differentiation with subsequent upregulation occurring upon
lineage commitment(57). Although unclear at this time, one can speculate that in line
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with myeloid-based models of HSC differentiation, it is plausible that MafB regulates the
balance of lineage potential and commitment early in CMLPs and later in p-MBTs.
A5. IFN-γ. The Th1 cytokine Interferon-gamma (IFNγ) plays a paradoxical role
in pathologic states and MDSC expansion. IFNγ’s proapoptoic and antiangiogenic effect
in innate and adaptive immune responses have made this cytokine an attractive therapy
for numerous hematologic malignancies. IFNγ production has been demonstrated to
prevent the development of both primary and transplanted tumors. However, it is
increasingly recognized that IFNγ may have negative oncological outcomes, specifically
with regard to tumor development(110). In particular, IFNγ production by antigenactivated T cells synergizes with MDSC-produced IFNγ to further enhance the
suppressive function of MDSCs in a STAT1 dependent and independent manner(111).
Conversely, blockade of IFNγ production diminishes MDSC-mediated T cell
suppression(58). Perhaps this controversial role of IFNγ can be attributed to its
production unique to a given pathological condition and regulation of interferon
regulatory factor-8 (IRF-8). Known as the interferon consensus sequence binding protein
(ICSBP), IRF-8 is a member of the IRF family of IFN-α and IFN-β dependent
transcription factors(112). However, IRF-8 is sensitive to IFNγ and is expressed in
hematopoietic myeloid and lymphoid progenitors. Within these cells, IRF-8 serves as a
positive modulator of the EBF/E2A transcription system, which regulates B cell
development (Figure 2)(113). IRF-8 is also a negative modulator of PU.1, master
regulator of myelopoiesis. Inhibition of PU.1 alleviates PAX-5 suppression, which is
required for normal B cell development(114). The interplay between PU.1 and B cell
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development is further supported by the observation in which ectopic expression of PU.1
and C/EBPa induces macrophage cell fate in developing B cells(115). In the absence of
IRF-8, PU.1 activity is not inhibited and myeloid differentiation is promoted(113,116).
This is further supported in IRF-8 deficient mice which develop chronic myelogenouslike syndrome (CML) subsequent to robust MDSC accumulation(117). Thus, tumorinduced IFNγ dysregulation and IRF-8 reduction would be expected to skew
hematopoiesis away from lymphoid development towards myelopoiesis.
A6. VEGF. Vascular endothelial growth factor (VEGF) is a prototypic growth
factor consisting of five family members with tissue specific physiological effects that
signal through either of the two high affinity tyrosine kinase receptors: VEGFR1, c fmslike tyrosine kinase (Flt1) and VEGFR2, fetal liver kinase-1 (Flk-1)(118,119). The
upregulation and contribution of VEGF to pathogenesis and hematopoietic dysregulation
has been well documented in many cancer patients and animal models of
neoplasia(120,121). Within the BM microenvironment, VEGF is secreted by HSCs to
ensure cellular survival. In particular, VEGF-deficient HSCs are unable to repopulate in
lethally irradiated mice, even with co-administration of WT HSCs. Conversely,
stimulation of VEGFR1 rescued their survival of these cells in vivo and in vitro
administration of VEGF promoted colony formation. These results indicate that VEGF
may regulate hematopoiesis in a cell-autonomous manner by establishing an autocrine
loop(120). This assumption is further supported by the autocrine production of VEGF by
malignant myeloid precursors in leukemic patients, leading to mobilization of immature
myeloid progenitors upon stimulation of both VEGFR1 and VEGFR2(121). VEGF itself
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binds CD34+ hematopoietic progenitors via VEGFR1, enhancing CD34+ MPP and MEP
early progenitor cell production while skewing hematopoiesis in favor of myeloid
development. This observation supports the myeloid-based model of hematopoiesis,
since an increase in VEGF stimulation can induce lineage redistribution of p-MBT cells.
In fact, VEGF increased CD34+ progenitor cell production with myeloid and lymphoid
potential from mouse embryonic stem cells. Furthermore, these cells have been
demonstrated to form myeloid colony forming units as well as B220+, CD19+ B
lymphocytes when cultured on stromal cells in the presence of IL-2 and IL-7(122).
VEGF differentially regulates hematopoietic alterations contingent upon
stimulation of a given VEGFR subpopulation. Signaling through VEGFR1 boosts
populations of immature Gr-1+ myeloid and B lymphocytes. Furthermore, ablation of
VEGFR1 is associated with decreased HSC survival and differentiation(119,123).
VEGFR1 activation likewise populates the immature myeloid cell compartment by
inhibiting the transcription factor NFkB in hematopoietic progenitors. Continuous
infusion of VEGF abrogates NFkB and downregulates stimulatory FLT3L, thereby
reducing DC differentiation and maturation. As a consequence, the immature myeloid
compartment is further populated(124). This observation is consistent with observations
that alterations in NF-kB subunits induce enhanced myelopoiesis and reduced
lymphopoiesis(125). The behavior of VEGFR1 is in direct contrast to that mediated by
VEGFR2 activation, which promotes CD11b+Gr-1+ MDSCs at the expense of B cells at
the pro-B cell state(126). In particular, continuous infusion of VEGF results in decreased
lymphoid compartment concomitant with increased myeloid populations, thereby
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inducing splenomegaly(124). The consequence of increased VEGF signaling in
dysregulated hematopoiesis perhaps occurs through VEGF/VEGFR modulation of pMBT cells, redirecting their commitment towards lymphoid or myeloid cells.
III. Accumulation and differential activity of MDSC subsets in disease.
As mentioned earlier and demonstrated by Figure 3, MDSC induction occurs in a
myriad of disease states, impairing both the innate and adaptive arms of the immune
response. MDSCs exert most deleterious effects on T cell activation via the release of
small soluble oxidizers, the impairment of T-cell-antigen recognition, and the depletion
of essential amino acids from the local extracellular environment. This MDSC mediated
immune

suppression

and

impairment

of

cancer

immunotherapy

is

well

established(66,127). However, these studies are challenged by observations in which
MDSCs are not always immunosuppressive. Reports suggest that the immunostimulatory
or immunoinhibitory potential of MDSCs depends upon the dual role of nitric oxide, the
cytokine milieu, the interaction between MDSCs, T cells, other myeloid cells, and the
tumor microenvironment. In fact, infections with microorganisms can skew MDSCs
towards

antitumor

properties

and

for

this

reason,

Salmonella-based

cancer

immunotherapies have been pursued with promising preclinical results(128,129).
Furthermore, by limiting immune activation, MDSCs serve a beneficial role in
transplantation, autoimmunity, and sepsis(130,131). These paradoxical observations are
due to the differential accumulation and activity of granulocytic Ly6G+ (G-MDSC)
monocytic Ly6C+ (G-MDSC) subtypes in disease progression. Although much attention
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has been dedicated to elucidate MDSCs as a group, a thorough characterization of each
subset is required to demonstrate that despite being categorized as a heterogeneous group
of cells, G-MDSCs and M-MDSCs are functionally and phenotypically distinct.
A. Cytokine consortium of M-MDSC and G-MDSC development.
The phenotypic and functional characteristics of MDSCs underscore their
myeloid origin. Common cytokines involved in myeloid commitment that are
dysregulated in cancer and other disease states have been implicated in the induction of
MDSCs. These factors include M-CSF, GM-CSF, IL-6, VEGF, and G-CSF. Thus the
unique immune response elicited by a given pathological condition can lead to the
accumulation of MDSCs. Moreover, as demonstrated in Figure 4, the subsequent
cytokine consortium dictates the accumulation of monocytic or granulocytic MDSCs.
GM-CSF and G-CSF are two cytokines predominately associated with in vivo MDSC
accumulation and in vitro MDSC generation(35,132). GM-CSF is recognized as a critical
hematopoietic cytokine, mediating the differentiation of myeloid progenitors into
granulocytes, eosinophils, monocytes, megakaryocytes, and erythrocytes. G-CSF and its
receptor are critical regulators of steady state and emergency granulopoiesis. G-CSF
promotes the survival, mobilization, and proliferation of myeloid progenitor cells
alongside neutrophil differentiation. Several studies indicate that each cytokine
preferentially induces granulocytic or monocytic MDSCs. Exposure to GM-CSF alone
induces immunosuppressive M-MDSCs while G-CSF induces G-MDSCs(133,134). In
fact, glioblastoma patients exhibit high levels of G-CSF concomitant with G-MDSC
accumulation(135). Under steady state conditions, G-CSF acts in concert with CXCR2
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ligands, CXCL1 and CXCL8 to induce mobilization and recruitment of neutrophils,
respectively. Therefore, it has been proposed that G-CSF may promote expansion of GMDSCs via CXCL1 and mobilization via CXCL8(136). In terms of GM-CSF, Dolcetti et
al. demonstrated that a 4T1 mammary cancer cell line deficient in GM-CSF but not GCSF, is less immunosuppressive due to the differential expansion of G-MDSCs over MMDSCs(134). The reduced tumor growth is accompanied by an increase in antigen
specific T cells in lymph nodes of mice challenged with GM-CSF deficient 4T1. These
mice also exhibited an accumulation of G-MDSCs that did not affect the generation of
tumor specific T cells(137). Moreover, Greten and colleagues indicate that human CD14+
monocytes purified from healthy donors can be differentiated into suppressive MMDSCs upon co-culture with IL-4 and GM-CSF(132). Interestingly, the combination of
GM-CSF and G-CSF induces M-MDSCs from BM cells after 4-day co-culture.
Additionally, IL-1β has been indicated to inhibit NK cell differentiation in favor of GMDSCs in 4T1 mammary carcinoma(138,139). Lastly, Simpson and colleagues
demonstrate that the inflammatory cytokine, macrophage inhibitory factor (MIF),
induces M-MDSC differentiation rather than G-MDSCs(140).
B. Immunophenotyping.
Although MDSCs collectively represent a heterogeneous cell population with
different patterns of surface proteins, they are unified by expression of Gr-1 and CD11b
in the murine system. The Gr-1 epitope consists of Ly6C and Ly6G molecules that are
members of the Ly-6 family of low molecular weight phosphatidylinositol-anchored cell
surface glycoproteins(135,141,142). Gr-1high Ly6G+ G-MDSCs morphologically
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resemble polymorphonuclear granulocytes while Gr-1low Ly6C+ M-MDSCs resemble
mononuclear monocytes. Studies indicate that engagement of Gr-1 epitope through Ly6G
or Ly6C can differentially regulate myeloid cell activity and the subsequent immune
response(136,141,143). For example, ligation through Ly6G can induce cell death while
Ly6C ligation can lead to cellular expansion and differentiation. In addition to Gr-1 and
CD11b in the murine system, both populations are also identified by functional markers
such as Dectin-1, a non-toll like pattern recognition receptor, death receptor FAS, and
ADAM17 (144-146). In humans, MDSC subset accumulation is dependent on the type of
tumor but overall defined as Lin-HLA-DR-CD33+ and further categorized into monocytic
CD14+ and granulocytic CD15+ cells(127).
As summarized in Figure 5, many groups have reported the utilization of other
markers to further delineate G-MDSCs and M-MDSCs. In humans, G-MDSCs are
defined as CD11b+CD33+CD14loCD15hi and further characterized by expression of
CD66b, a member of the carcinoembryonic antigen family that is commonly expressed
on human neutrophils. G-MDSCs have also been indicated to express VEGFR1 and low
levels of CD62L(147-149). Although these surface proteins are often associated with
neutrophils, the main differentiating factor between G-MDSCs and neutrophils is the
immunosuppressive capabilities of G-MDSCs. In contrast to neutrophils, G-MDSCs are
purified from the mononuclear cell fraction in a density gradient of peripheral
blood(147). Furthermore, other groups report IL-4Rα (CD124) in patients with non-small
cell lung cancer(150) and higher levels of S100 proteins, S100A8/A9 complex as
compared to S100A9 on M-MDSCs, in patients with head and neck squamous cell
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carcinoma (HNSCC)(151). Human G-MDSCs express IL-13R under suppressive
conditions and lower levels of CD33 as compared to M-MDSCs(127,152,153). In the
murine system, Youn and colleagues demonstrated the expression of M-CSFR and
utilization of CD244 as a marker of G-MDSC cells with T cell suppressing activity. The
authors indicate that CD244+ G-MDSCs are capable of inhibiting antigen specific T cell
responses while CD244- G-MDSCs are unable to do so(154). Additionally, Toh et al.
report that G-MDSCs express CXCR2 (IL-8Rβ), which binds CXCL1, CXCL2, and
CXCL5. G-MDSCs also express CXCL1 and CXCL2 while tumors express CXCL5. The
ligation of these particular molecules leads to the accumulation of G-MDSCs and not MMDSCs in the tumor microenvironment. In fact, inhibition of CXCR2 inhibited GMDSC trafficking to primary melanoma tumor(7). This is supported by another finding
in a murine model of traumatic spinal cord injury, indicating the expression of CXCR1
and CXCR2 on G-MDSCs(155).
M-MDSCs are mainly defined as CD11b+CD33+CD14hiCD15lo in humans and as
CD11b+Gr-1intLy6G- Ly6C+ in mice. In addition to S100A9 and CD124 as mentioned
above, M-MDSCs are also characterized by expression of CCR2, which is mainly
expressed by monocytes and not granulocytes(111). In tumor conditions, CCR2 induces
monocyte trafficking from the BM, limits entry of tumor specific T cells into the tumor
microenvironment, and leads to T cell inhibition by MDSCs in a contact-dependent
manner.

Murine

M-MDSCs

are

further

defined

by

CD49d,

CCR7,

and

CX3CR1(132,155,156). Another group reported the presence of F4/80 and CD93 on MMDSCs in the context of Experimental Autoimmune Encephalomyelitis (EAE)(157).
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C. Mechanism of action.
While the immunosuppressive functions of MDSCs are highly pleiotropic, the
mechanism of action differs according to each subset. Compared to M-MDSCs, GMDSCs are not very suppressive unless present in high numbers(111,134,137). GMDSCs are thought to induce antigen specific T cell suppression while M-MDSCs
promote both antigen specific and non-specific T cell suppression. This is a consequence
of a differential enzymatic, signaling, and cytokine profile of each subset.
C1. Enzymatic activity. While both populations of MDSCs express arginase 1
(Arg1), reactive oxygen species (ROS) and inducible nitric oxide (iNOS) are specific to
G-MDSCs and M-MDSCs, respectively(35). Arg1 is widely expressed in murine
myeloid cells but limited to neutrophils in humans. The expression of Arg1 allows GMDSCs to promote cancer progression via T cell suppression but also limit graft versus
host disease (GVHD)(150,154). Arg1 acts by consuming the essential amino acid Larginine (L-Arg) and metabolizes it to L-ornithine and urea, thus depleting critical
components of cellular proliferation and detoxification(158). In vitro L-Arg depletion by
MDSCs inhibits antigen-specific T cell proliferation in OT-1 and OT-2 transgenic mice.
Furthermore, in the absence of L-Arg, T cells exhibit decreased CD3ζ expression, Jak-3,
NFΚB-p65 translocation and IFN-γ production(148,159). CD3ζ is an essential component
of the T cell receptor (TCR), imperative for the intracellular signaling cascade and
subsequent T cell activation(160). Loss of L-Arg decreases cyclin D mRNA
transcriptional rate as well as translation, thus arresting T cells in G0-G1 phase(161).
However the depletion of L-Arg does not result in apoptosis, and both CD3ζ expression
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and proliferative potential can be restored upon L-Arg administration(162). In addition to
Arg1, G-MDSCs induce T cell suppression via the production of ROS. Although ROS
can be produced by several mechanisms, NADPH oxidase (NOX2) is primarily
responsible for ROS production in leukocytes(163). The main consequence of MDSCmediated ROS production is inhibition of T cells in an antigen-specific manner by
inducing MHC class-I restricted T cell tolerance(164). Nagaraj et al. report that ROS
nitrates tyrosine residues on CD8 and TCR to alter peptide recognition but does not
induce T cell deletion(165). Finally, G-MDSCs limit NK-cell responses via H2O2
production(166). However, additional experiments are required to further elucidate the
mechanism of this interaction.
M-MDSCs are more potent suppressors of the immune response(111). Perhaps
one of the main contributions of M-MDSC in pathologic conditions is the upregulation of
iNOS, which generates NO. Mazzoni et al. report that NO production by MDSCs blocks
peptide-specific T cell proliferation. Further analysis revealed this results from
prevention of T cells entering the cell cycle. Interestingly, this was reversible; after T
cells were stimulated with Con A in the presence of MDSCs, they regained their
proliferative potential upon removal of MDSCs. Thus, it is plausible that although MMDSCs prevent T cell proliferation, they do not induce apoptosis but transiently induce
T cell suppression(167). The contribution of NO is further elucidated by the observation
that MDSCs generated from iNOS-deficient mice are not suppressive(168). Another
deleterious consequence of iNOS is the consumption of L-arginine; under conditions of
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limited L-Arg concentration, NOS produces peroxinitries (ONOO2), which are strong
oxidizing agents that nitrate proteins and cause T cell apoptosis(164,169).
C2. Cytokine production. Although cytokine profile is disease dependent,
emerging literature is beginning to identify each population of MDSCs with certain
cytokines. For example, G-MDSCs secrete TNF-α upon exposure to LPS, INFγ, and
TGF-β while M-MDSCs mainly produce IL-6, IL-10, IL-23, TGF-β, and VEGFα(132,156). The cytokine consortium subsequently affords the observed differential role
of each subset. In fact, the concomitant secretion of IL-10 and TGF-β also allows MMDSCs

to

be

potent

inducers

of

CD4+CD25+Foxp3+

T-regulatory

cells(132,136,156,170).
C3. STAT signaling. Both M-MDSCs and G-MDSCs signal through Janus
Kinase (Jak) / signal transducer and activator of transcription (STAT) pathways(95,97).
STAT proteins are latent cytoplasmic transcription factors activated by a variety of
hematopoietic and immune-mediated cytokine receptors. M-MDSCs utilize STAT1 to
induce downstream T cell suppression(111). Of the STAT signaling pathways, STAT3
has been strongly linked with MDSC proliferation and survival(56,111). STAT3 also
promotes the activity of MDSCs, particularly Arg1 in CD14+ M-MDSCs(171). Using the
receptor tyrosine kinase inhibitor, sunitinib, Ko and colleagues demonstrated differential
STAT3 and STAT5 signaling in M-MDSCs and G-MDSCs. The authors indicate that
sunitinib downregulates STAT3, subsequently abrogating M-MDSC proliferation and
impairing G-MDSC survival. However, the addition of GM-CSF provided protection via
STAT5 signaling(172).
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C4. Interaction with other cells. Recent findings are beginning to suggest that
mast cells (MCs) contribute to the recruitment and activity of MDSCs(10,173,174).
While MCs have well been documented to mediate allergic inflammation, their
demonstrated involvement with neoplastic disease is more recent. Mast cells accumulate
in the tumor microenvironment and correlate with poor prognosis(175). This is partly a
consequence of the secretion of various pro-inflammatory cytokines such as TNF-α, IL6, IL-10, IL-13, and IL-17(176). MCs facilitate MDSC migration to the tumor
microenvironment via the utilization of 5-lipoxygenase and IL-17(173,174).
Perhaps another intriguing component of MDSC/MC interaction is the biogenic
amine, histamine. Although MCs have previously been known to be the major
contributors to the histamine pool, recent studies indicate that other myeloid cells can
produce histamine, albeit at lower levels(177). Endogenous histamine is generated via
the conversion of L-histidine to histamine by histidine decarboxylase (HDC). Histamine
acts on a spectrum of cell types through G-protein coupled receptors, Histamine Receptor
(HR) 1 – HR4. Studies demonstrate that histamine alters the Th1/Th2-attracting
chemokine distribution, leading to a more pronounced Th2 response. In fact, co-culture
of monocytes with histamine increases IL-10 but inhibits IL-12 cytokine production by
the monocytes, further skewing towards Th2 immunity(178,179). It was recently
reported the HR antagonists can lead to MDSC apoptosis and subsequent tumor
regression(180). Intriguingly, while both G-MDSCs and M-MDSCs express HR1 and
HR2, the net affect of histamine appears to be subset specific(181). Indeed, HR2
blockade is more effective in limiting M-MDSC activity(180). Exogenous administration
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of histamine promoted the expansion and proliferation of M-MDSCs rather than GMDSCs.
Macrophages are capable of fighting both intracellular and extracellular
pathogens and are thus classified into two distinct subsets according to the cytokines
required for their activation and the pathogens they target(182). Classically activated M1
Macrophages are normally activated by IFN-γ or LPS to release NO and TNF-α in
targeting intracellular pathogens as well as IL-12 and IL-23(183). M1 macrophages are
better able to partake in antigen presentation and T cell activation as compared to
alternatively activated M2 macrophages. Upon stimulation by IL-4 or IL-13, M2
macrophages secrete IL-10, TGF-β, and upregulate Arg-1 in response to extracellular
pathogens(184). MDSCs have not only been shown to interact with macrophages but also
resemble M2 macrophages. MDSCs decrease IL-12 production by macrophages and
skew their differentiation towards an M2 phenotype and macrophages in turn promote
MDSC IL-10 production(185). Although the authors of this study did not differentiate
the subset of MDSCs, it can be deduced based on morphology and cytokine production
that this interaction is mainly within the monocytic fraction.
Another cell known to interaction with MDSCs are dendritic cells (DCs).
Dendritic cells are professional antigen presenting cells that identify, process, and present
antigens to naïve, resting T cells(186). This is critical for the generation of an appropriate
immune response. MDSCs secrete IL-10 that abrogates toll like receptor (TLR) ligation
and subsequent IL-12 production by DCs. This in turn reduces DC mediated T cell
activation(187). While MDSCs as a group have been shown to limit DC maturation, a
32	
  

recent study indicated that CD14+ M-MDSCs impair the quality of a DC vaccine. The
authors indicate that M-MDSCs not only prevent DC maturation but also antigen
presentation and migration(188). Interestingly, MDSCs can also be converted to DCs.
Two studies have been done to this effect, one indicating the requirement of NKT Cells
and a-galactosylceramide; and another suggesting interaction of iNKT with CD1d on
MDSCs(132,139,156,189).
D. Expansion and activation.
D1. Survival and Proliferation. G-MDSCs have a reduced life-span, similar to
the 3.8 days reported for neutrophils and are more sensitive to cryopreservation as
compared to M-MDSCs(150,190,191). However, G-MDSCs are quickly repopulated
from the BM and exhibit up to 80% survival when exposed to tumor explant supernatant
and GM-CSF(136,147,154,190). This has been attributed to delayed apoptosis by
increased CXCL8(192). Despite the prolonged life-span, these conditions do not induce
G-MDSC proliferation. This has led to the current notion that M-MDSCs are the main
subset capable of proliferation. In fact, in the same study, Youn et al. demonstrated that
splenic M-MDSCs incorporated more than twofold more BrdU as compared to GMDSCs in tumor bearing mice(170).
D2. Polarization and differentiation. In addition to a shorter life span, GMDSCs are also incapable of differentiation, while M-MDSCs can give rise to mature
myeloid cells(154). In fact, CD11b+Gr-1+CCR2+CX3CR1low M-MDSCs can mature into
DC and macrophages under appropriate stimuli(156). A recent study indicates that MMDSCs can also differentiate into G-MDSCs via epigenetic silencing of the
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retinoblastoma gene. Interestingly, the same study also suggests that G-MDSCs can lose
their immunosuppressive characteristics and become phagocytic upon ex vivo exposure
to tumor explant supernatants and GM-CSF(170).
Moreover, MDSCs can be polarized towards immunostimulatory type1 or
immunoinhibitory type2 cells. Murine Paired immunoglobulin-like receptors A and B
(PIR-A and PIR-B) along with human PIR homologues belong to the immunoglobulin
super family. These molecules have recently been demonstrated to differentially regulate
MDSC polarization. PIRs were first identified as homologues to the human Fc receptor
for immunoglobulin A (IgA). It has recently been reported that PIR signaling can alter
polarization of M-MDSCs between classically activated proinflammatory phenotype
(M1) and alternatively activated anti-inflammatory (M2) phenotype. PIR-A delivers
activation signals in complex with a homodimeric Fc common γ chain, which harbors an
immunoreceptor tyrosine-based activation motif (ITAM), resulting in cytokine
production in myeloid cells(193-195).In contrast, PIR-B engagement results in negative
signal transduction upon phosphorylation of immunoreceptor tyrosine-based inhibitory
motifs

(ITIMs)

and

recruitment

of

SH2-homology–containing

protein-tyrosine

phosphatase-1 (SHP-1) and SHP-2. In fact, SHP1 inhibition can shift M2 M-MDSCs to
M1-MDSCs. Furthermore, Fridlender et al. demonstrated that G-MDSCs can also be
polarized between G1 and G2 phenotypes, but this is dependent upon TGF-β signaling.
MDSCs and tumor cells secrete large amounts of TGF-β that induces pro-tumor G2 GMDSCs. However, blockade of TGF-β signaling via TGF-βR antagonization
reprogrammed G2 G-MDSCs to tumoricidal G1 G-MDSCs(196).
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E. Subset accumulation in pathological conditions.
E1. Neoplasia. The expansion of MDSC phenotypes is dependent upon the
immunoregulatory factors altered by a given tumor model (Fig. 6). In humans, MMDSCs are mostly associated with melanoma, prostate, lung, gastrointestinal, and
hepatocellular carcinoma while G-MDSCs are associated with breast, colon, pancreatic,
bladder, HNSC carcinoma(132). A detailed list is summarized elsewhere, but the overall
trend is the dominant accumulation of G-MDSCs(132,136,156,170).
In naïve mice, MDSCs comprise 2-4% of total nucleated splenocytes with a 3:1
ratio of G-MDSC to M-MDSCs(132). However, MDSCs can increase to 50% of total
splenocytes with a 5:1 G-MDSC to M-MDSC ratio in tumor bearing mice(170). The
population of G-MDSCs becomes consistently increased in all tumor models, whereas
the frequency of monocytic MDSCs is only signiﬁcantly increased in a few models such
as EL-4 and ANV. Only in mice bearing Lewis Lung Carcinoma, G-MDSCs and MMDSCs are equally elevated(197). In humans, G-MDSCs are found to be the most
abundant population in solid tumors while M-MDSCs are more frequent in
leukemia(198). Moreover, in a given host, G-MDSCs tend to locate at the primary tumor
site (24.5%) vs spleen (4.2%), while M-MDSCs are found in cutaneous tumors (3.9%)
vs. spleen (2.8%) (7). This is further supported by the observation that MDSC depletion
results in reduction of primary but not cutaneous tumors(7). In a mouse model of
Multiple Myeloma, M-MDSCs begin to accumulate within one week of tumor induction
while G-MDSCs accumulate weeks later. Despite the delay in kinetics, G-MDSCs
continue to be the dominant population both in the BM and peripheral blood(199). In
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tumor bearing mice, G-MDSCs are recruited out of the BM in response to stromal cell
derived factor-1α (SDF-1α), ligand for CXCR4. In humans with renal cell carcinoma
(RCC) and HNSCC, G-MDSCs accumulation is associated with an increase in
intratumoral and serum expression of CXCL8 (IL-8), a potent inducer of neutrophil
motility to sites of inflammation(192). This is corroborated by another report indicating
the importance of CXCR2 ligand in the recruitment of G-MDSCs to primary tumor sites.
In fact, G-MDSCs were 5 times more abundant as M-MDSCs, and CXCR2 inhibition
significantly abrogated their migration(7).
While most attention has been given to the pathogenic mechanisms of MMDSCs, G-MDSCs are now beginning to be appreciated for their contribution to tumor
progression. Using a model of spontaneous melanoma, Toh and colleagues found that GMDSCs are needed for the early stages of cancer dissemination, as late depletion did not
alter metastasis to skin, lymph nodes, and lungs. Additionally, upon co-culture with GMDSCs, NBT-II bladder carcinoma cells acquired a mesenchymal morphology,
consisting of actin microfilament redistribution and downregulation of E-Cadherin. This
was attributed to the production of Hepatocyte Growth Factor (HGF) and TGF-β, known
inducers of epithelial-mesenchymal transition (EMT). Moreover, the same study reported
that G-MDSCs promoted tumor cell proliferation in a contact-independent manner(7).
E2. Infection. MDSCs, predominantly G-MDSCs, have been shown to
accumulate during infections with microorganisms. In this context, they play a beneficial
role in limiting unwanted inflammation. In fact, mice unable to expand MDSCs exhibit
markedly higher mortalities to sepsis-associated inflammation(56,200,201). As
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mentioned earlier, bacterial infections can skew MDSCs towards antitumor properties.
The administration of attenuated Salmonella enterica serovar Typhimurium vaccine
(RASV) results in an accumulation of MDSCs, particularly G-MDSCs. These MDSCs
were tumorcidal, sensitive to LPS stimulation, and released large amounts of TNF-α.
RASV treatment reduced Her-2/neu expressing tumor growth, shifted MDSC
differentiation towards G-MDSCs, and enhanced anti-tumor CTL responses. It is for this
reason that Salmonella-based cancer immunotherapies have been pursued with promising
preclinical results(202,203). Furthermore, by limiting immune activation, MDSC play a
protective role in sepsis. Delano et al. demonstrated that polymicrobial sepsis induced
significant MDSC accumulation. Additional reports are surfacing and lending support to
the protective role of MDSCs in microbial infections, especially Pseudomonas
aeruginosa colonization in burn victims(56). More recently, it was reported that murine
MDSCs express dectin-1, a non-Toll-like pattern recognition receptor for β-Glucans,
which are the main components of numerous bacteria, fungi, and yeast cell walls. The
authors report that whole β-Glucans particle (WPG) administration preferentially
enhanced the survival of G-MDSCs but did not induce their differentiation. In contrast,
WPG treatment reduced M-MDSC survival but promoted differentiation towards
CD11c+F4/80+ non-immunosuppressive cells. Moreover, M-MDSCs were no longer able
to suppress T cell proliferation in the presence of WPG(145). This could be attributed to
the fact that WPG reduced NO and Arg1 expression in M-MDSCs while it did not alter
ROS expression in G-MDSCs.
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While the accumulation of MDSCs in parasitic infection has been reported, the
immunomodulatory potential of these cells remains largely unknown(204). However,
MDSCs have recently been characterized in Trypanosoma cruzi infection. The protozoan
parasite is the causative agent of myocarditis that manifests in Chagas disease. MDSCs
comprise the majority of the inflammatory cell infiltrates in the heart. The most abundant
subset in this case is M-MDSCs (70%) as compared to G-MDSCs (20%)(205). The
authors of this finding indicate that this is mainly mediated via CCL2 chemokine.
Interestingly, these infiltrating M-MDSCs in the heart do not traffic from the BM but
rather become replenished from the spleen. Like those isolated from the tumor
microenvironment, the infiltrating M-MDSCs also express high levels of Arg and iNOS,
and inhibit T cell proliferation. Given another report indicating the accumulation of GMDSCs in the peripheral organs of T. cruzi infected mice, it is possible that G-MDSCs
and M-MDSCs preferentially migrate to specific anatomical sites in a given disease
state(205,206).
E3. Autoimmunity. Experimental autoimmune encephalomyelitis (EAE) is a
well characterized and utilized murine model of human multiple sclerosis (MS). While
MDSC expansion has been reported, conflicting results exist surrounding subset
accumulation and contribution to MS. Zhu et al. found M-MDSCs to be the dominant
population shortly after EAE induction, comprising 30% of infiltrating inflammatory
cells in the central nervous system (CNS). They suggest that M-MDSCs can have both
protective and harmful roles in the CNS in that they can suppress excessive T cell
activation but damage neuronal tissue via NO over-production(157). In a separate
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investigation, Yi et al., while also reporting M-MDSCs accumulation in EAE, suggest
that M-MDSCs promote the pathogenesis of EAE. In this model, MDSCs induced Th17
differentiation from naïve CD4+T helper cells via IL-17A production and upregulation of
orphan nuclear receptor RORA and RORC. The severity of EAE was reduced upon
MDSC depletion(207). Although contradictory to our understanding of MDSCs, this
observation is supported by another model of MS, which utilizes Theiler’s murine
encephalomyelitis (TMEV), a natural mouse pathogen known to promote demyelination
in susceptible strains. Parallel to Zhu et al.’s observations, M-MDSCs comprise the
majority of infiltrating immune cells in TMEV infected mice and contribute to myelin
attack and inflammation in the CNS. M-MDSC depletion resulted in diminished viral
load, reduced T cell accumulation, and increased IFN-γ and IL-12 production with
simultaneous IL-10 reduction(157,208). The disease promoting capability of M-MDSCs
in this context is a salient contradiction to the MDSC paradigm, since given the overall
immunosuppressive nature of MDSCs; one would anticipate that M-MDSCs would limit
EAE progression. This negative role of MDSCs and dominant accumulation of MMDSCs is challenged by Ioannou and colleagues. The authors demonstrated that GMDSCs are the major population that expand in EAE and serve a protective role. They
showed that AT of G-MDSCs decreases the severity of EAE via immunosuppression
induced by PD-L1-PD-1 ligation. The authors argue that the disparity in these findings
results from the inflammatory milieu induced in each model as well as emphasis on the
effects of MDSCs on Th17 expansion or the immunosuppressive nature of MDSCs(209).
Perhaps these controversial findings can be remedied by the observation that the
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damaging activity of MDSCs in MS lies within the M-MDSC population and beneficial
within G-MDSCs.
E4. Chronic inflammation/ metabolic dysregulation. Although both subsets of
MDSCs are associated with inflammation, M-MDSCs are the main pro-inflammatory
subset. In a report by Zigmond et al., M-MDSCs were shown to promote inflammatory
bowel disease (IBD) via the release of IL-6, IL-23, VEGF-α, and induction of
iNOS(156). IBD is defined as a heterogeneous group of chronic inflammatory disorders
of the gastrointestinal tract with two major forms-Crohn’s disease and ulcerative
colitis(210,211). While the therapeutic potential of MDSCs in inflammatory disease has
been proposed, a recent study by Su et al. demonstrates that G-MDSCs could be the
subset most effective. The authors report that G-MDSCs can be purified from BM of
naïve mice and subsequently utilized for AT in a model of murine colitis. G-MDSCs,
albeit not entirely curative, relieved inflammation, increased survival rate, and decreased
disease score(211).
Traumatic spinal cord injury (SCI) results in significant acute inflammation,
characterized by mobilization of immune cells, including MDSCs and production of
proinflammatory cytokines. Using a murine model of SCI, Saiwai and colleagues
demonstrated that M-MDSCs are the most abundant population. The authors attribute
this preferential accumulation to the expression of CCR2 by M-MDSCs. They indicate
that M-MDSCs exhibit higher expression of anti-inflammatory mediators such as IL-10,
TGF-β, and VEGF while G-MDSCs express IL-1β and TNF-α. The infiltrating MMDSCs accelerated the removal of hematomas and enhanced the coagulation process,
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promoting tissue repair. They also demonstrated that IL-10 released by M-MDSCs
induces heme-oxygenase 1 expression in macrophages, which prevents heme
toxicity(155,212). Thus the authors argue that AT of M-MDSCs can have therapeutic
anti-inflammatory benefits not only in SCI but other disease states involving severe
inflammation.
Obesity is known to induce a low-grade chronic inflammatory state and it has
recently been associated with MDSC accumulation. Taking advantage of mice
genetically predisposed to obesity; Xia et al. demonstrated that both G-MDSCs and MMDSCs expand with increased weight and higher fasting glucose. They report that
MDSC depletion leads to impaired insulin sensitivity and glucose tolerance that can be
remedied upon AT of MDSCs. This increase in MDSCs is restricted mainly to the liver
and other peripheral organs while BM levels remain comparable to lean mice. The
authors argue that in this case, MDSCs inhibit proinflammatory cytokines such as IL-6
and TNF-α and skew macrophages towards insulin sensitizing, alternatively activated M2
macrophages. This suggests that the AT of MDSCs promotes a Th2 skewed immune
response(213).
IV.

Dissertation Objective.
To address the role of ADAM10 in hematopoietic cell differentiation, we

generated a strain of mice overexpressing ADAM10 at early stages of HSC development.
These mice (A10Tg) not only allowed for the elucidation of ADAM10 in cell
differentiation but also gave rise to myeloid derived suppressor cells. After confirming
that A10Tg MDSCs were similar to tumor-derived MDSCs, we utilized A10Tg MDSCs
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to address the differential activity of granulocytic and monocytic MDSC subsets in
neoplasia and helminth infections in an environment devoid of confounding tumors and
tumor-derived factors. Furthermore, A10Tg MDSCs were exploited to further dissect the
interaction of mast cells and mast cell released histamine with MDSCs.
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MATERIALS AND METHODS
I.

Mice.

A. ADAM10 transgenic mice.
ADAM10 transgenic (A10Tg) mice were generated with the ADAM10-pHSE3’
transgene construct.

ADAM10-pHSE3’ was produced by subcloning the murine

ADAM10-HA cDNA from mADAM10-pcDNA3.1/Zeo into the previously described
pHSE3’ vector, containing the murine H-2Kb promoter and IgH enhancer regulatory
elements(214-216). Briefly, the ADAM10-HA cDNA was excised using BamHI/SalI and
ligated into BamHI/XhoI cut pHSE3’. ADAM10-pHSE3’ was amplified and analyzed by
restriction endonuclease digestion and sequence analysis. A 7.5-kb XhoI fragment
containing both cDNA and regulatory elements was excised from ADAM10-pHSE3’ and
injected into C57BL/6 (A10Tg line 240) or C57BL/6 x Balb/c (A10Tg line 258) embryos
by the Virginia Commonwealth University Transgenic/Knockout Mouse Core. The
resulting offspring were screened for the presence of the ADAM10-HA cDNA by PCR
analysis

of

genomic

tail

DNA

using

CCGACAGTGTTAATTCTGCTCC-3’)

ADAM10
and

cDNA

sense

(5’-

anti-sense

(5’TTCTTTCAGCCAGAGTTGTGCG-3’) primers. Amplification of DNA from A10Tg
founders generated a 652-bp PCR product.

Transgene integrity was verified and

transgene copy number determined for both A10Tg lines by Southern blot analysis.
Briefly, genomic tail DNA from both founders and their F2 progeny was digested with
AccI and electrophoresed on a 0.9% agarose gel, and the injection fragment from
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ADAM10-pHSE3’ was used as both probe and copy number control. A10Tg line 258
was backcrossed with C57BL/6 mice for at least five generations.
B. Mast cell deficient mice.
Genetically mast cell-deficient c-kit mutant mice were purchased from Jackson
laboratory. These mice carry spontaneous loss-of-function mutations at both alleles of the
dominant white spotting (W) locus (i.e., c-kit). They exhibit a marked reduction in c-kit
tyrosine kinase-dependent signaling, resulting in disrupted normal mast cell development
and survival(217). The Cpa3-Cre; Mcl-1fl/fl mice (C57BL6 background) are a generous
gift from Dr. Stephen Galli and express Cre recombinase under the control of a segment
of the carboxypeptidase A3 (Cpa3) promoter. C57BL/6-Cpa3-Cre; Mcl-1fl/fl mice are
severely deficient in MCs and basophils with no other apparent hematologic
changes(218).
C. Other mice.
C57BL/6 and congenic CD45.1+ (B6-Ly5.2) mice were purchased from Jackson
Laboratories and the National Cancer Institute, respectively. Pmel-1 mice were progeny
of breeding pairs purchased from Jackson Laboratories.
II. Cell Lines.
OP9-GFP and OP9-DL1 cells were kindly provided by J.C. Zuniga-Pflucker (University
of Toronto) and maintained in OP-9 medium as previously described(6). Lewis Lung
Carcinoma (LLC) cell line was obtained from the American Type Culture Collection
(ATCC) and maintained in DMEM as per ATCC’. B16-melanoma and B16-GM-CSF
cells were provided by H. Bear and maintained as previously described(219).
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III. Adoptive immunotherapy (AIT) of B16-melanoma.
AIT

subsequent

to

B16-melanoma

challenge

was

performed

as

previously

described(219). Briefly, donor WT or pmel-1 mice were sensitized in the left footpad
with 1x106 B16-GM-CSF melanoma cells. Ten days later, popliteal draining lymph
nodes were harvested, dispersed into a single cell suspensions in complete RPMI 1640
(cRPMI) at 1x106 cells/mL, and activated with bryostatin 1 (5 nM, provided by the
National Cancer Institute), ionomycin (10nM, Calbiochem) (B/I), and rIL-2 (80U/mL,
Chiron) at 37°C for 18 h. Cells were washed 3x with cRPMI 1640, resuspended at 1–
2x106 cells/mL in the presence of IL-7 and IL-15 (10 ng/mL each, Peprotech), cultured
for five days and maintained at 1-2x106 cells/mL in the presence of fresh cytokines.
Recipient mice were injected i.v. with 0.25x106 B16-melanoma cells. Three days
subsequent to B16 inoculation and one day prior to AIT treatment, mice were pre-treated
i.p. with 2 mg cyclophosphamide (CYP, Mead Johnson). For gemcitabine treatment,
mice were injected i.p. with 1.2 mg three days prior to B16 challenge and every five days
thereafter. For AIT, 2x107 expanded donor cells were washed (2x) in PBS, ﬁltered
through a 70-µm nylon mesh strainer (Invitrogen), and injected i.v. in recipient B16challenged mice. No systemic cytokines or vaccinations were administered to these
tumor-bearing mice. After 14 days, mice were euthanized by CO2 inhalation and lungs
were harvested, fixed in 10% formaldehyde, and black lung nodules were counted under
a dissecting scope. When nodules were too many to count they were given a value of
250.
IV. ARG and NO detection.
45	
  

A. Arginase.
MDSCs were purified from A10Tg and LLC bearing mouse spleens, cytoplasmic
extracts were prepared and tested for arginase activity by the production of urea as
described in manufacturers instructions (DARG-200, BioAssay Systems). Briefly, 1 X 106
splenic MDSCs were purified and washed with PBS and centrifuged at 1000Xg at 4oC
for 10 min. Pellets were then lysed for 10 min in 100 uL of 10mM Tris-HCL (PH 7.4)
containing 1 mM pepstain A, 1 mM leupeptin, and 0.4% Triton X-100. Subsequently,
cells were centrifuged at 10,000Xg at 4oC for 10 min and transferred to 96-well plates,
incubated for 30 mins at 37oC with arginine (4X) and Mn (1X) buffer. Arginase reaction
was then stopped using 200 uL of urea reagent and incubated at RT for 60 mins. The urea
concentration was then measured by light absorption at 520 nm wavelength using a
microplate reader.
B. Nitric Oxide.
Nitric Oxide was measured using Greiss Reagent per manufacturers instructions
(Molecular Probes, G7921). Briefly, 150µL of cell supernatants were mixed with 20 µL
of Greiss reagent (1% sulfanilamide in 5% phosphoric acid and 0.1% N-(1naphthyl)ethylenediamine dihydrochloride), and 130 µL of deionized water. After 30
min incubation at RT, the absorbance was measured by light absorption at 548 nm
wavelength using a microplate reader.
C. Arginase 1 and iNOS Quantitative PCR.
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MDSCs were isolated as previously described and cultured with MCs or 100µM
histamine (Invitrogen) for 24 hours. RNA was extracted and cDNA was generated as
previously described(220). Primers for running an iQ SYBR Green Supermix (Biorad)
quantitative PCR (qPCR) assay were purchased from IDT. Primers are as listed for Arg1
forward 5’-GAC CAC AGT CTG GCA GTT GG-3’, Arg1 reverse 5’-TGG TTG TCA
GGG GAG TGT TG-3’, iNOS forward 5’-CAC CCC AAG TTC GAC TGG TT-3’ and
iNOS reverse 5’-CTA AAG GGA CAG GCG CTG AA-3’. Results were analyzed with
Biorad iQ5 real-time PCR software (version 2.0)
V. B16 Challenge and MDSC adoptive transfer (AT).
C57/BL6 WT and mast cell deficient KitWsh/Wsh mice were given 5-10 X 106 A10Tg
MDSCs via tail vein injection one day prior to challenge with 0.25x106 B16-melanoma
cells. In the subpopulation studies, WT mice were injected with the same amount of
either granulocytic or monocytic fraction of MDSCs. Mice were then injected again with
5-10 X 106 A10Tg MDSCs every three days for three weeks. Mice were then euthanized
by CO2 inhalation and lungs were harvested, fixed in 10% formaldehyde, and black lung
nodules were counted under a dissecting scope as described above.
VI. BMMC culture.
Mouse bone marrow-derived mast cells (BMMC’s) were derived from femurs of WT
mice and cultured in cRPMI 1640 containing 10% FBS, 2mM L-glutamine, 100 U/mL
penicillin, 100µg/mL streptomycin, 1mM HEPES (Quality Biological, Inc.), and 1mM
sodium pyruvate (Cellgro). Cultures were supplemented with IL-3-containing
supernatant from WEHI-3 cells and stem cell factor (SCF)–containing supernatant from
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BHK-MKL cells. The final concentrations of IL-3 and SCF were adjusted to 1ng/mL and
10ng/mL, respectively. Mature BMMC were used after 28 of days of culture.
VII. BMMC co-culture with A10Tg MDSCs.
BMMCs were washed and resuspended at 0.5X106 cells/mL; half were loaded with
0.5ug/mL of mouse IgE (Purified mouse IgE kappa isotype control, BD Pharmingen) in
10ng/mL of recombinant IL-3 24hrs prior to the co-culture. Following MDSC isolation,
BMMCs were washed twice and cultured at a 1:1 ratio with MDSC in 10ng/mL IL-3 and
10ng/mL GM-CSF (PeproTech, Rocky Hill, NJ) overnight. Dinitrophenylated human
serum albumin (DNP-HSA) was added to all wells at a concentration determined to be
optimal for MC activation (20-100ng/mL). Supernatants were collected 6 or 18 hours
after cross-linking and kept at -80°C until analysis by ELISA.
VIII. Bone marrow chimera studies.
Recipient CD45.2+ A10Tg (F240) and CD45.1+ WT mice were irradiated with 950 rads
using a

137

Cs source (Mark I , Model 68-0146; JL Shepherd & Associates). Donor

Lineage-Sca-1+c-Kit+ (LSK) cells were isolated from mouse tibia, femur, and humerus by
magnetic cell sorting with a lineage cell depletion kit. (MACS; Miltenyi Biotec). 24
hours after irradiation, recipient CD45.2+ A10Tg and CD45.1+ WT mice were injected
i.v. with 2.5x106 CD45.1+ WT and 5x106 A10Tg LSK cells, respectively. For generation
of mixed BM chimeras, a mixture of LSK cells from CD45.2+ A10Tg (2.5x106) and
CD45.1+ WT (1.25x106) mice were injected i.v. in to irradiated CD45.1+ WT mice. Cell
populations were analyzed 42 and 63 days after reconstitution.
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IX. Determination of supernatants, serum, or cellular cytokine levels by ELISA and
Multiplex Assays.
A. MC/MDSC co-culture supernatants.
All ELISAs for MDSC/MC co-cultures were obtained from Peprotech and used as per
manufacturer’s instructions. Supernatants collected after 6hrs were analyzed for TNF-α
and supernatants collected after 18hrs were analyzed for IL-6, IL-13, and MIP-1 α.
B. Serum cytokine levels.
Serum from Nb infected mice were collected and analyzed for cytokines using the
Millipore Milliplex Mouse Cytokine Panel and Bio-Rad Bioplex according to the
manufacturer’s guidelines.
C. Hepatic MDSCs.
Livers were harvested from Nb infected mice on Day 7 post infection and AT with
MDSCs from A10Tg spleens. Livers were isolated as described(221). Recovered liver
MDSCs as well as MDSCs isolated from A10Tg spleens were cultured for 48hrs in
cRPMI. Supernatants were harvested and cytokines were analyzed with a Bioplex Pro
Multiplex Cytokine Assay (Biorad).
X. Flow cytometry and cellular imaging.
Cell isolation and labeling were conducted as previously described(6). Additionally,
peritoneal fluid cells were obtained by flushing the peritoneal cavity with PBS (5mL).
BM cells were isolated by flushing excised tibias and femurs with cRPMI. Single cell
suspensions of PLN cells, thymocytes, and splenocytes were created by disrupting
inguinal, brachial, axillary lymph nodes, thymus, and spleens, respectively, with glass
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slides. Cells were labeled following red blood cell lysis and filtration through 40µM cell
strainers. Antibodies included anti-mouse unlabeled 2.4G2, biotinylated CD135 (A2F10),
FITC-conjugated IL7R (A7R34), anti-CD62L (MEL-14), CD44 (IM7), B220 (RA36B2), and Gr-1 (RB6-8C5); PE-conjugated Ly6G (A18), B220, CD8 (53-6.7), Gr-1, Ter119, Thy1.2, (30-H12) CD11b (M1/70), CD3ε (2C11); APC-labeled B220, Ly6C
(HK1.4)CD4 (RM4-5), CD5 (53-7.3), CD45.2 (104) and c-kit (2B8); PE/Cy7-conjugated
CD11b and sca-1 (D7), PE/Cy5 CD34 (A2F10), APC/Cy7-conjugated CD19 (6D5) and
CD45.1 (A20), PerCP/Cy5.5-conjugated IL-7R, IgM (RMM-1); and anti-human
PERCP/Cy5.5 CD15 (W6D3); and CD33 (WM-53) all from Biolegend. CD34-FITC
(RAM34), Ly6G-FITC (1A8), c-kit-PE (2B8), Sca-1-PE/Cy7, and APC-conjugated CD3
(145-2C11),B220 (RA3-6B2), Ly6C/Ly6G (RB6-8C5), CD11b (M1/70), and TER-119
(TER-119) from BD Biosciences, and ADAM10-FITC (FAB946) from R&D Systems.
PE/Cy5-conjugated anti-mouse HR1 (polyclonal) from Bioss; FITC anti-human HLADR (LN3), APC anti-human CD11b (ICRF44), and PE anti-human CD14 (61D3) from
eBiosciences Anti-mouse FcgRII/III (in-house) and anti-mouse Ly6D (49-H4) (BD
Biosciences) were biotinylated with EZ-Link Sulfo-NHS-biotin (Pierce), followed by
dialysis to remove free NHS-biotin. Streptavidin-ECD (Beckman Coulter) was used for
secondary labeling of biotinylated-Ly6D and FcgRII/III labeled cells. Flow cytometric
analysis was performed using a Canto or AriaII (BD Biosciences), and data analysis was
conducted with FCS Express V3 software. Histogram overlays were generated in
SigmaPlot 10.0. as line plots and smoothed using the SMOOTH transform. For
fluorescence activated cell sorting (FACS) of LSKs, lineage positive cells were depleted
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with a lineage cell depletion kit (MACS; Miltenyi Biotec/ Stemcell Technologies).
Remaining LSKs (Lin-IL7R-ckithisca-1hi) were sorted with an Aria II. Lineage positive
cocktail included anti-CD3ε, Gr-1, CD11b, B220, and Ter119 antibodies. Splenic
MDSCs (CD11b+Gr-1+) were sorted for photomicrographs. Purity exceeded 95% and
were subsequently cytospun on glass slides and stained with the HEMA 3 stain set
(Fisher Scientific). Photographs were taken with a BIOQUANT NOVA camera attached
to an Olympus BH-2 microscope.
XI. Human MDSCs.
A. Allergic patients.
Human studies were conducted under Institutional Review Board (IRB) protocol #MCC13740 for cancer patients and 00870 for allergic patients. All patients had the capacity to
give informed consent to participate in this research. Twenty mLs of blood was collected
in EDTA coated vacuum tubes from allergic patients identified as symptomatic or nonasymptomatic controls and peripheral blood leukocytes were isolated using Ficoll-Paque
separation medium (GE Healthcare) according to manufacturer’s protocol.
B. Cancer patients.
For the isolation of MDSCs from the peripheral blood of a stage I primary breast cancer
patient, erythrocytes were lysed from whole blood treated with ACK lysing buffer. Total
leukocytes were then stained and sorted into a CD33+ CD11b+ HLA-DRlo/- population,
representative of MDSCs, into 100% FBS using a Becton Dickinson FACSAria III.
Flow cytometry was performed on pretreatment MDSCs and 48hr post addition of
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histamine or RPMI alone on a BDCanto II. Data analysis was conducted using FlowJo
software v10.0.5.
XII. Isolation of MDSCs, AT, and labeling.
Spleens were harvested from A10Tg or LLC bearing WT mice, depending upon
experimental protocol. They were then dispersed into single cell suspensions and filtered
through 70-µm nylon mesh strainers (Invitrogen). Erythrocytes were lysed using an
ammonium chloride potassium (ACK) lysing buffer (Quality Biological). Gr-1+, Ly6G+,
or Ly6C+ cells were purified using the Easy Sep PE-selection kit (Stem Cell
Technologies) according to the manufacturer’s protocol. For AT studies, 5-10 x 106
naïve MDSCs were injected into the tail vein of each experimental group every three
days. For AT of dye labeled MDSCs, PKH26GL dye linker kit was purchased from
Sigma and MDSCs were stained according to the manufacturer’s protocol.
XIII. LSK cultures.
BM-derived LSK cells were isolated via magnetic cell sorting and FACS, were cultured
in the presence of IL-7 (1 ng/mL, Peprotech) and Flt3L (5ng/mL, R&D Systems) on
OP9-GFP or OP9-DL1 as previously described(26). LSK differentiation was examined
via flow cytometric analysis, and differentiated cells were passed onto freshly plated OP9
cells with additional cytokines every 4-5 days. Compound E (100nM, Alexis
Biochemicals) and GI254023X (5µM, Glaxo Smith Kline) were used for blockade of γsecretase and ADAM10 activity, respectively.
XIV. MDSC/Histamine Cultures and Migration Assays.
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Five million MDSCs were cultured with 100µM histamine (Invitrogen) and counts were
made with trypan blue dead cell exclusion daily for three days. For dose response assays,
MDSCs were cultured with 5µM, 10µM or 100µM histamine (Invitrogen).All cell
concentrations started with 50,000 cells/well. After 48 hours of growth, a 24hr pulse of
[H3]-thymidine, 1mCi/mL (Perkin Elmer) was used. Plates were then harvested using a
Filtermate cell harvester onto GFC plates. Assays were read using a Topcount Plate
Counter (Perkin Elmer, Waltham, MA). For migration assays, 2 x 105 B16 melanoma
cells, 2 x 105 MCs derived from BMMC or media alone were loaded into the lower well
of 8 micron transwell plates (Costar). 2 x 105 MDSCs were loaded into the upper well.
Plates were incubated for four hours at 37 oC and the lower well was harvested for flow
cytometry to determine migration through the membrane.
XV. N. brasiliensis infection, gemcitabine treatment, and HR antagonization.
A. Nb infection.
N. brasiliensis (Nb) larvae were generously provided by Joe Urban (Agriculture
Research Station, Beltsville, MD) and were maintained as previously described(222).
A10Tg or WT animals were infected with approximately 650 L3 Nb in groups of four or
more. Alternatively, Kitwsh/wsh mice and WT controls were infected with approximately
500 L3 Nb. Additional groups of animals were sacrificed on Day 7 post infection and the
proximal halves of the small intestines were harvested. Adult worms were then purified
and enumerated. Fecal egg burdens were assessed on days 5-13 and enumerated on
McMaster counting chamber slides. Serum was collected by tail vein nick on days 7, 14,
21 and 35.
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B. Gemcitabine treatment.
For mice injected with GEM, 1.2 mg was injected i.p. starting on Day 0 and repeated
every five days throughout the experiment. For AT studies, WT mice were injected with
5-10 X 106 A10Tg MDSCs via tail vein injection starting at day four of infection and
repeated every three days thereafter. MDSCs were incubated with FITC labeled anti-Gr1(Biolegend, RB6.C85) and selected using anti-FITC magnetic beads (MACS, Milteyni
Biotec).
C. HR antagonization.
Mice were injected with cetirizine (CT), 0.5mg/kg in 100µl saline i.p. starting on day -1
and repeated daily. For cimetidine (CIM), 20mg/kg was injected in 100µL saline i.p.
starting on day -1 and repeated every two days thereafter.
XVI. Proliferation Assays.
MDSCs were cultured for 15 mins with 10µM CT, CIM, or alone prior to the addition of
5µM, 10µM or 100µM histamine (Invitrogen).All cell concentrations started with 50,000
cells/well. After 48 hours of growth, a 24hr pulse of [H3]-thymidine, 1mCi/mL (Perkin
Elmer) was used. Plates were then harvested using a Filtermate cell harvester onto GFC
plates. Assays were read using a Topcount Plate Counter (Perkin Elmer, Waltham, MA).
XVII. T cell suppression assays.
For polyclonal T cell activation, CD90.2+ T cells (6.67x104) were sorted from spleen via
FACS and activated with immobilized anti-CD3 (2C11, 10µg/mL) and soluble antiCD28 (37.51, 1µg/mL) in 96-well plates. Sorted CD11b+ MDSCs (Ly6G+, Gr-1+, and
Ly6G-) from A10Tg or LLC tumor bearing mice were then added at increasing T
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cell:MDSC ratios. To achieve a total cell number of 2x105/well, CD90.2- WT
splenocytes were added. For antigen-specific T cell suppression assays, soluble gp100
(1µg/mL) was added to defined ratios of pmel-1 transgenic splenocytes (6.67x104) and
A10Tg MDSCs. In both situations, after 54hrs of culture, 1µCi of [3H]-thymidine was
added to each well for an additional 18 hrs and thymidine incorporation was measured.
XVIII. Western Blot.
A. ADAM10.
Whole cell lysates (30ug) of BM cells generated with lysis buffer containing 0.5% NP40
and protease inhibitors (Roche) were applied to SDS-PAGE and blotted on nitrocellulose
membranes. Blots were probed with HRP-conjugated anti-mouse β-actin (SigmaAldrich) or unlabeled rabbit anti-ADAM10 (AnaSpec Inc.) followed by HRP-conjugated
anti-rabbit IgG (Southern Biotech). Chemiluminescence was visualized with the Pico
chemiluminescent kit (Pierce).
B. HR expression.
For HR1 and HR2, five million naïve MDSCs were lysed and prepared as described
above. Blots were stained with an H1 Receptor (P-20) and H2-I/Adβ (5K43) both from
Santa Cruz, for HR1 and HR2 and detected with Rabbit F(ab’)2 Anti-Goat IgG and Goat
Anti-Mouse IgG1-HRP respectively both from Southern Biotechnology Associates, Inc.
Equal loading was confirmed by staining with Monoclonal Anti-β-Actin-Peroxidase,
antibody produced in mouse from Sigma.
C. STAT signaling.
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Five million Ly6G+ or Ly6C+ cells were cultured for 24 hours with 10µM histamine,
harvested and lysed in Cell Lysis Buffer (Cell Signaling) on ice for 30 minutes following
the manufacturer’s protocol. Proteins were run on a NuPage 10% Bis-Tris gel
(Invitrogen) and then transferred to nitrocellulose. Blots were stained with pSTAT5
(Y694) from Cell Signaling and pSTAT3 (Tyr 705)-R from Santa Cruz. Detection was
performed with Goat anti-Rabbit IgG (H+L)-HRP from Southern Biotechnology
Associates, Inc. and detected with SuperSignal West Pico Chemiluminescence Substrate
(Thermo Scientific).
XIX. Statistical Analysis
P-values were calculated using unpaired two-tailed Student’s t-tests or unpaired MannWhitney analysis in Graphpad Prism v5. Error bars represent the SEM between samples.
p<0.05 is considered statistically significant.
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RESULTS
I. ADAM10 overexpression alters
dysregulating S2/S3 cleavage of Notch.

hematopoietic

cell

differentiation

by

A. Generation of ADAM10 transgenic mice.
To examine the role of ADAM10 in hematopoiesis, we generated A10Tg mice
that overexpress murine ADAM10 cDNA under control of the H-2Kb promoter and the
IgH enhancer region (Fig. 7A). These transcriptional regulatory units were previously
utilized to generate multiple transgenic mouse lines, including TCR, CD23, and bkl
transgenics.

Thus

this

vector

allows

expression

in

early

lymphocyte

progenitors(215,223,224). Inclusion of the IgH enhancer results in preferential
expression on B lineage cells. Two founder lines, F240 and F258, were generated, and
Southern blot analysis of genomic DNA from F2 progeny demonstrated that both lines
contain similar copy numbers of the transgene (Fig. 7B). Because progeny of both lines
have nearly identical phenotypes, the following data are presented from line F240, unless
otherwise stated.
B. ADAM10 overexpression prevents B2 but not B1 lymphocyte development.
Western blot and flow cytometric analysis demonstrated that transgene
expression resulted in elevated levels of ADAM10 in BM cells, including pro/pre B cells
(B220+IgM-) (Fig. 8A-C). Unexpectedly, overexpression markedly reduced the levels of
pro/pre B cells and immature B cells (B220hiIgM+) in BM (Fig. 8A). This led to a near
complete loss of peripheral B cells in peripheral organs including blood, lymph nodes
and spleen (Fig. 9A). Analysis of B cells from peritoneal fluid revealed that levels of B1a
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(B220intCD11b+CD5+) and B1b cells (B220intCD11b+CD5-) in A10Tg mice were not
significantly altered compared to littermate (LM) controls, whereas B2 cells
(B220hiCD11b-CD5-) were nearly absent (Fig. 9B). Thus, the block in B cell
development was specific to BM-derived B2 cells.
C. Reduced thymocyte progenitors in A10Tg mice.
Transgene expression suppressed development of thymocyte progenitors. A tenfold reduction was observed in Lin-CD44+c-kit+ early thymocyte progenitors (ETPs) in
A10Tg BM compared to LM (Fig. 9C). Accordingly, A10Tg mice exhibited reduced
levels of total, DN and DP thymocytes concomitant with a small thymus. However,
numbers of single positive thymocytes and peripheral T cells in PLN and the spleen were
not altered in A10Tg mice (Fig. 9D).
D. MDSC expansion in A10Tg mice.
Concomitant to the reduction in lymphocyte levels, A10Tg animals exhibited
significant myeloid accumulation. In fact, the spleens of A10Tg mice were noticeably
enlarged, weighing an average of 2.5 fold more than LM spleens and contained twice as
many nucleated cells (Fig. 10A). The forward and side scatter pattern of A10Tg
splenocytes indicated the presence of large granular myeloid cells (Fig. 10B). While the
majority of WT CD11b+Gr-1+ cells differentiate into mature myeloid cells prior to
exiting the BM, A10Tg CD11b+Gr-1+ cells expanded in BM, constituting 93.5% of BM
cells, and entered the spleen and PBL at dramatically high levels (Fig. 10C). CD11b+Gr1+ cells outside the bone marrow are classified as MDSCs, consisting of monocytic
(CD11b+Gr-1intLy6G-) and granulocytic (CD11b+Gr-1hiLy6G+) subsets(111). Light
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micrographs of sorted A10Tg CD11b+Gr-1+ splenocytes and flow cytometry confirmed
that A10Tg mice contain both monocytic and granulocytic MDSCs in PBL and spleen
(Fig. 10D-F).
E. ADAM10 prevents commitment of CLPs to the B cell lineage.
The expansion of myeloid cells in conjunction with blockade of B2 cell
development in A10Tg mice indicates that ADAM10 may regulate the commitment of
BM progenitors to myeloid or lymphoid lineages. Thus, we attempted to determine the
developmental stage at which this occurs. According to the classical model of
hematopoiesis, HSCs in the BM develop into CMPs that differentiate into myeloid cells
or CLPs that give rise to early thymocyte precursors or pro-B cells(34). Although a small
level of B220+ cells was present in A10Tg, further analysis revealed that they express
CD11b and Gr-1 (Fig. 11A,B), indicating that alterations in hematopoiesis occur prior to
the pro-B cell stage. This prompted us to examine the levels of HSCs, CLPs, and CMPs
in A10Tg mice. Analysis of BM lineage positive cells (Ter119, CD3ε, CD11b, Gr-1) and
CD19+ cells demonstrated the near absence of Lin-CD19+ B cells in A10Tg mice.
However, the percentage of Lin-CD19- cells was similar to LM levels (Fig. 12A). LinCD19- LM cells contain B220+ early B cell precursors, which were absent from A10Tg
BM (Fig. 12B). Lin-CD19-B220- cells can be further divided based upon IL-7 receptor
(IL-7R) expression. Gating on IL-7R- cells demonstrated that the percentage of HSCs
(Lin-CD19-B220-IL-7R-c-kithiscahi) was slightly lower in A10Tg BM, while the
percentage of CMPs (Lin-CD19-B220-IL-7R-c-kithisca+) was 2-fold higher than the level
of LM CMPs (Fig. 12C). In contrast, analysis of IL7R+ cells revealed a 2-fold decrease in
59	
  

CLP (Lin-CD19-B220-IL-7R+c-kitintscaint) levels in A10Tg BM (Fig. 12D). Additionally,
Inlay et al. recently demonstrated that Ly6D+ CLPs are committed to the B cell lineage,
whereas Ly6D- CLPs are uncommitted lymphoid progenitors(225). In accordance with
their report, 89% of LM B220+ cells and 30% of LM CLPs expressed high levels of
Ly6D (Fig. 12E,F). However, only 0.16% of A10Tg CLPs were Ly6D+(Fig. 12E).
Finally, A10Tg HSCs and CMPs do not overexpress ADAM10 on the cell surface.
However, 55.3% of A10Tg CLPs express elevated levels of ADAM10 compared to
28.4% of LM CLPs (Fig. 11C). These findings indicate that hematopoietic alterations in
A10Tg mice occur prior to the commitment of CLPs to the B cells.
F. ADAM10 alters myeloid but not LSK development.
To further determine the stage at which A10 overexpression altered cell
differentiation, we analyzed numerous subsets of LSK cells and myeloid precursors. As
mentioned above, multiple studies have shown that BM LSK cells can be subdivided into
various distinct populations based upon CD34 and fms-related tyrosine kinase 3 (Flt3)
expression: CD34-Flt3- long-term HSCs (LT-HSCs), CD34+Flt3- short-term HSCs (STHSCs), and finally CD34+Flt3+ multipotent progenitor populations (MPPs)(44,226,227).
We therefore analyzed these distinct populations within the LSK compartment in A10Tg
mice. Although the percentage of LSK cells was slightly lower in A10Tg BM (Fig. 13A),
we did not observe any differences in the levels of LT-HSC, ST-HSCs nor MPPs
between LM and A10Tg mice (Fig. 13C). However, the percentage of myeloid
progenitors (Lin-c-kithisca-) in A10Tg mice was approximately 2-fold greater than the
level in LM mice (Fig. 13B). It was previously shown that myeloid progenitors can also
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be subdivided into three distinct populations based upon CD34 and low affinity IgG Fc
receptors (FcgRII/RIII). These include CD34+FcgRII/IIIlo Common Myeloid Progenitors
(CMP), CD34+FcgRII/IIIhi Granulocyte-Macrophage Progenitors (GMP), and CD34FcgRII/IIIlo Megakaryocyte-Erythroid Progenitors (MEP)(44). As indicated above, there
is a striking difference in the myeloid compartment of A10Tg compared to LM BM.
GMP and MEP populations are nearly absent from A10Tg mice. Additionally,
approximately 80% of the A10Tg myeloid progenitors are in the CMP stage compared to
31.6% in the LM. This finding may account for the systemic expansion of CD11b+Gr-1+
MDSCs in A10Tg mice but not other mature myeloid cells such as neutrophils or
macrophages.
G. ADAM10-mediated hematopoietic dysregulation is cell-intrinsic.
To confirm that the observed phenotype was the result of transgene expression by
hematopoietic cells and not a dysregulation in the BM stromal environment, mixed BM
assays were conducted. Irradiated CD45.2+ A10Tg hosts were reconstituted with LSK
cells from WT CD45.1+ congenic mice, and irradiated WT CD45.1+ congenic hosts were
reconstituted with CD45.2+ A10Tg LSK BM cells. Despite being in a WT host, A10Tg
BM recapitulated the observed alteration in hematopoiesis of A10Tg mice: lack of B
cells and increased MDSCs(Fig. 14A). Despite being in an A10Tg host, WT BM cells
demonstrated normal cell differentiation: higher levels of B cells and minimal circulating
MDSCs (Fig. 14B). This indicated that altered cell differentiation in A10Tg mice was
due to alterations in signaling pathway(s) within hematopoietic cells rather than the
microenvironment. Mixed BM chimera studies further confirmed this, as irradiated
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CD45.1+ WT hosts were reconstituted with a mixture of LSK BM cells from CD45.2+
A10Tg and CD45.1+ WT donors. This resulted in similar reconstitution of host BM by
A10Tg and WT donor cells. Hematopoietic development of CD45.1+ WT cells was
similar to development in LM control mice, and development of CD45.2+ A10Tg cells
closely mimicked development in A10Tg mice. MDSCs only expanded from A10Tg BM
cells, and B lineage cells predominantly differentiated from WT BM (Fig. 15A,B). These
results demonstrate that ADAM10-mediated MDSC expansion is not the indirect result
of abrogated B cell development, trans-cleavage of BM stromal cell ligands, nor cytokine
secretion, which would cause WT MDSC expansion. They also illustrate that ADAM10
overexpression on hematopoietic cells causes MDSC expansion via an intrinsic cell
autonomous mechanism.
H. ADAM10 overexpression alters hematopoiesis by dysregulating Notch signaling.
Recent studies have demonstrated a critical role for ADAM10 and perturbed
Notch signaling in embryonic, thymocyte, and MZB development(12,14,228). Therefore,
to further elucidate this interaction and determine the effect of ADAM10 overexpression
on Notch signaling in HSC development, we cultured purified HSCs from LM and
A10Tg mice on OP9 stromal cells that lack Notch ligand (OP9-GFP) or express Notch
ligand, Delta-1, (OP9-DL1). The addition of IL-7 and Flt3L promote WT HSC
differentiation into T cells on OP9-DL1 cells and differentiation of B cells on OP9-GFP
cells(229). Examination of OP9-GFP cultures showed that while LM HSCs developed
into B cells, A10Tg HSCs only generated CD11b+Gr-1+ myeloid cells (Fig. 16A).
Analysis of OP9-DL1 cultures demonstrated that A10Tg HSCs are capable of T cell
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differentiation in the presence of Notch ligand (Fig. 16B). However, their development
was delayed compared to LM HSCs. This further supports the adverse effect of
ADAM10 overexpression on early thymocyte development.
I. Differential effects of S2 and S3 cleavage of Notch.
In order to further test the hypothesis that ADAM10 overexpression perturbs
Notch signaling, we examined the effects of dysregulating Notch signaling in LM and
A10Tg HSCs. Inhibition of Notch signaling with the addition of a γ-secretase inhibitor
(GSI) or the ADAM10 inhibitor (GI254023X) to OP9-DL1 cultures prevented LM and
A10Tg T cell development (Fig. 16C). In accordance with reports of ADAM10’s critical
role in Notch S2 cleavage in other cell types, this result demonstrates that ADAM10 also
mediates S2 cleavage in developing hematopoietic precursors(12,16,20). Most
interestingly, although both inhibitors equally blocked Notch-dependent T cell
differentiation, their effects on the development of myeloid and B lineage cells were
distinct. ADAM10 inhibition in OP9-DL1 cultures resulted in B cell development of LM
and A10Tg HSCs, whereas GSI inhibition caused myeloid expansion (79.4% of LM and
76.7% of A10Tg cells) that was strikingly similar to the myeloid differentiation of
A10Tg cells in OP9-GFP cultures (88.5%) (Fig. 17A). Additionally, ADAM10 inhibition
in OP9-GFP cultures not only resulted in enhanced LM B cell development, but it also
rescued B cell development of A10Tg cells and prevented myeloid differentiation (Fig.
17B). This further supports our finding that ADAM10 activity inhibits B cell
development. Finally, GSI treatment of LM OP9-GFP cultures had no effect on HSCs,
demonstrating that GSI treatment directs myeloid development only upon S2 product
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accumulation. Accordingly, A10Tg HSCs exclusively developed into Gr-1+ myeloid
cells in the absence of ligand or following GSI treatment. However, ligand engagement
and GSI activity prevented S2 accumulation and myeloid development in LM and A10Tg
cultures. Thus, these results indicate that ADAM10 overexpression may also direct
myeloid development by generating excessive S2 product that is not processed in the
absence of ligand-induced γ-secretase activity.
II. A10Tg MDSCs are analogous to tumor-derived MDSCs and require MCs for
their activity.
A. A10Tg MDSCs are analogous to tumor-induced MDSCs.
Although MDSC accumulation is a byproduct of ADAM10 overexpression in
early hematopoietic progenitors, ADAM10 expression is not altered in these cells.
Therefore, we examined whether A10Tg mice could be exploited to study MDSCmediated immune regulation in an environment devoid of confounding tumor derived
factors. To this end, we conducted T cell proliferation assays with A10Tg MDSCs in
order to ensure that A10Tg derived MDSCs are functional. Accordingly, ex vivo T cell
suppression assays were performed. A10Tg MDSCs inhibited T cell proliferation of both
A10Tg and WT purified T cells with anti-CD3/anti-CD28 polyclonal T cell stimulation
(Fig. 18A, B). We also tested antigen specific T cell stimulation using T cells from pmel1 mice, which have T cell receptor transgenic that specifically recognize the melanocyte
differentiating antigen gp100 peptide(230). Indeed, MDSCs purified from A10Tg mice
also suppressed antigen specific T cell proliferation (Fig. 18C). Like tumor-derived
MDSCs, A10Tg MDSCs also consists of two subsets: granulocytic (CD11b+Ly6Ghigh)
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and more immunosuppressive monocytic (CD11b+ Ly6G-Ly6Chigh) subsets(231). As
demonstrated in Figure 18A-C, the more immunosuppressive Ly6G- population of
MDSCs suppressed T cell proliferation to a larger degree as compared to Ly6G+ or Gr-1+
MDSCs. Both A10Tg and tumor-induced MDSCs demonstrated similar differential T
cell suppression for these two subsets (Fig. 18D). Furthermore, A10Tg T cells also
exhibited reduced levels of L-selectin (CD-62L), a receptor required for homing of naïve
T cells to the lymph nodes (Fig. 18E,F), similar to what has been previously reported for
tumor-induced MDSCs(144). Additionally, MDSCs impair the T cell response through
the activity of arginase 1 (Arg1) and inducible nitric oxide synthase (iNOS)(232).
Accordingly, A10Tg MDSCs had comparable levels of these enzymes to tumor derived
MDSCs (Fig. 18G,H). These ex vivo observations indicate that MDSCs present in A10Tg
animals behave similarly to tumor-derived MDSCs.
B. M-MDSCs promote tumor progression and limit AIT.
The B16 melanoma model was employed to redundantly validate the
functionality of A10Tg MDSCs and to asses their in vivo contribution to tumor growth
and therapeutic intervention. This model is well established for characterization of
metastatic behavior and response to adoptive immunotherapy (AIT)(219). After two
weeks of challenge with B16, A10Tg animals were more susceptible to metastasis than
LM controls (Fig. 19A). In fact, A10Tg animals exhibited tumor nodules that were too
numerous to count and subsequently assigned a count of 250. AIT exerted a minimal
effect in A10Tg mice, suggesting that the presence of MDSCs diminished the activity of
adoptively transferred T cells. Conversely, while AIT treatment did not completely
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abolish metastasis in LM lungs, it nonetheless induced a significant decrease in tumor
load. This may be attributed to the use of non-antigen specific T cells and the lack of
lymphodepleting chemotherapy, highlighting the importance of lymphodepletion for
optimal activated T cell infusion in immunotherapy. Accordingly, our AIT protocol was
modified to incorporate the chemotherapeutic agents cyclophosphamide (CYP) and
gemcitabine (GEM). CYP lymphodepletes recipient mice, permitting homeostatic
proliferation of transferred T cells and GEM preferentially decreases MDSC levels in
tumor-bearing mice(233,234). A10Tg mice treated with GEM alone exhibited a response
comparable to their LM counterparts (Fig. 19B,C), demonstrating that T cell
functionality is retained upon MDSC depletion. Incorporation of GEM concomitant with
CYP and activated T cell transfer resulted in complete regression of metastasis in both
groups. Inspection of lungs from A10Tg mice illustrates the significant abrogation of
metastasis arising from tritherapy (Fig. 19D). It is important to note that in A10Tg mice,
GEM administration selectively diminished MDSCs levels but did not alter the
lymphocyte population (Fig. 20A).
The preceding experiments were performed using LM T cells. Given the
profound ability of MDSCs to suppress antigen-specific T cell stimulation, the ideal AIT
would utilize tumor-specific T cells alongside chemotherapy. Accordingly, our protocol
was adjusted to incorporate pmel-1 mice that are T cell receptor transgenic for gp100
melanoma peptide(219). As predicted, A10Tg MDSCs exerted parallel effects regardless
of antigen specificity. A10Tg mice had much higher metastasis levels than LM without
treatment and only responded favorably to AIT upon MDSC depletion (Fig. 20B). These
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studies indicate that A10Tg MDSCs promote tumor metastasis and compromise the
efficacy of cancer immunotherapy. Lastly, given the published literature and our
observation that M-MDSCs are more immunosuppressive than G-MDSCs, we conducted
AT of both MDSC subsets with B16 Melanoma. As shown in Figure 21, M-MDSCs
were more potent promoters of B16 colonization to the lungs compared to G-MDSCs.
Taken together, our data indicate that A10Tg MDSCs are functionally and
phenotypically parallel to tumor-derived MDSCs.
C. G-MDSCs enhance parasite clearance.
Next, we examined the effect of MDSCs on the immune response in helminth
infections. While MDSC accumulation with Nippostrongylus brasiliensis (Nb) has been
reported, the direct immunomodulatory role of MDSCs in anti-Nb responses has not been
examined(204). A WT response to Nb is characterized by production of Th2 associated
cytokines that ultimately mediate adult worm (L5) clearance 10-12 days postinoculation(235). Following Nb challenge, A10Tg animals had significantly reduced
fecal egg counts compared to WT controls (Fig. 22A). This is highly correlated with 50
percent reduction in L5 burden in A10Tgs (Fig 22B). This indicated that MDSCs may
facilitate parasite clearance. To determine if the increased worm clearance was correlated
with an increase in Th2 cytokines, we examined a panel of Th2 cytokines. Analysis of
peak infection (day 7) serum levels of IL-4, IL-5 and IL-13 demonstrated significantly
enhanced levels in Nb infected A10Tg animals as compared to infected LM (Fig. 22C).
Additionally IL-17 and IL-33, which have been reported to recruit MDSCs, were also
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elevated in serum of A10Tg mice(173,236). These serum cytokines then decreased as
infection began to decline (data not shown).
To determine whether enhanced Nb clearance is dependent on MDSC-activity,
MDSCs were depleted from A10Tg mice. GEM treatment resulted in elevated egg counts
in A10Tg mice similar to WT levels (Fig. 22A). However, GEM-mediated MDSC
depletion in A10Tg mice significantly exacerbated the peak level of Nb infection. Taken
together, the data indicate that the enhanced immune response in A10Tgs is a
consequence of elevated MDSC levels. Next, to eliminate off target effects of GEM,
A10Tg MDSCs were purified and adoptively transferred to WT mice over the course of
Nb infection. AT of MDSCs resulted in significantly reduced egg counts, comparable to
A10Tgs (Fig. 22A). To determine which MDSC subset was responsible for this
observation, MDSCs were purified based upon Ly6G and Ly6C expression and AT into
WT Nb infected mice. The Ly6Ghigh (G-MDSCs) population had the same effect as total
Gr-1+ purified MDSCs while the AT Ly6Chigh (M-MDSCs) had no effect. This indicates
that the granulocytic population of MDSCs mediates the anti-Nb immunity (Fig. 22E).
The direct of role of MDSCs was further supported in WT mice that were T cell
depleted. These mice exhibited the same rapid rate of clearance as WT mice infused with
MDSCs (Fig 22A). As expected, Nb clearance was significantly slower in T depleted
WT mice without AT of MDSCs (Fig. 22D).
D. Interaction with MCs is critical for MDSC-mediated Nb clearance.
Mucosal MC hyperplasia is a hallmark of gastrointestinal helminth infection
which enhances the immune response, leading to parasite clearance(237). In fact, mice
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deficient in MCs exhibit delayed clearance kinetics(238). Given that MCs mainly
produce Th2 polarizing and pro-inflammatory cytokines and that MCs chemoattract
MDSCs, we examined whether the interaction between the two cell types could be
contributing to the enhanced Nb expulsion. Surprisingly, AT of MDSCs into MC
deficient mice did not enhance Nb expulsion, indicating that a MDSC/MC interaction is
critical for MDSC-mediated anti-Nb responses (Fig. 22F). To assess this interaction ex
vivo, MCs were co-cultured with MDSCs. This resulted in synergistic increases in IL-6,
IL-13, TNF-α and MIP-1α (Fig. 23).
E. In the absence of MCs, MDSCs fail to promote B16 colonization to the lungs.
Given that MDSCs require MCs to enhance anti-Nb immunity, the B16
metastasis study was re-evaluated in MC deficient mice. Several groups have
demonstrated

that

MCs

recruit

MDSCs,

which

accumulate

in

the

tumor

microenvironment and correlate with poor prognosis(173,239,240). In addition, MCdeficient mice have decreased rates of tumor growth that increase to WT levels
subsequent to MC reconstitution(241). Therefore, we anticipated a lower degree of B16
metastasis in KitWsh/Wsh compared to WT controls, which would be enhanced in the
presence of MDSCs. To this end, KitWsh/Wsh and WT mice were injected with B16 with
and without AT of MDSCs. WT mice were more susceptible to B16 metastasis compared
to KitWsh/Wsh. Upon AT of MDSCs, WT mice exhibited similar levels of tumor nodules as
B16 A10Tgs, indicating the direct contribution of MDSCs to suppression of the immune
response. However, much to our surprise, AT of MDSCs into KitWsh/Wsh mice failed to
increase B16 metastasis (Fig. 24A,B). Thus, these results demonstrate that MDSCs
69	
  

promote B16 melanoma metastasis in a MC-dependent manner and indicate that
MC/MDSC interactions significantly enhance the MDSC-mediated suppression of
antitumor immunity but accelerate parasite clearance.
III. Histamine contributes to MC-mediated MDSC regulation.
A. MCs single-handedly promote MDSC-mediated parasite clearance.
To confirm that enhanced parasite clearance and necessity of MCs was not unique
to A10Tg MDSCs or our KitWsh/Wsh mice, similar studies were repeated with tumor
derived MDSCs as well as another strain of MC deficient mice. Mice were injected s.c.
in the flanks with Lewis Lung Carcinoma (LLC) cells and MDSCs were isolated from
tumor bearing mice and adoptively transferred into WT mice. As shown in 25, MDSCs
derived from LLC-bearing mice also accelerated Nb expulsion. This demonstrated that
our observations were not unique to A10Tg MDSCs. Additionally, to confirm that the
reduced parasite clearance in KitWsh/Wsh MC deficient mice was due to lack of MCs and
not the mouse model, KitWsh/Wsh were reconstituted with MCs. Upon reconstitution, AT of
MDSCs promoted parasite clearance similar to our observations in WT mice, suggesting
the requirement of MCs (Fig. 26). We further confirmed this observation using another
strain of MC deficient mice, Cpa3cre; Mcl-1fl/fl mice (C57BL/6 background). These mice
express Cre recombinase under the control of a segment of the carboxypeptidase A3
(Cpa3) promoter. C57BL/6-Cpa3cre; Mcl-1fl/fl mice are severely deficient in MCs and
basophils with no other apparent hematologic changes(218). Parallel to KitWsh/Wsh mice,
AT of MDSCs also failed to accelerate the clearance of Nb in the Cpa3cre; Mcl-1fl/fl mice
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(Fig. 27). Overall, these studies confirm that MCs are indeed required for MDSCmediated parasite clearance.
B. MCs induce MDSC migration and activation in the liver.
Given the literature highlighting MCs as attractants of MDSCs and the
importance of MDSC recruitment in an immune response, the trafficking behavior of
MDSCs was analyzed after AT in the presence or absence of MCs. To monitor their
migration, MDSCs were labeled with the PKH26GL lipid dye and AT i.v. into naïve
mice. In agreement with the published literature, we observed a preferential migration of
MDSCs 18hrs post AT to the liver (Fig. 28A)(221). To determine if this trafficking
pattern is utilized in helminth infection, MDSCs were labeled and infused i.v.
concomitant with Nb challenge in WT and KitWsh/Wsh mice. Indeed, MDSCs trafficked to
the liver in infected WT mice. However, the accumulation of MDSCs in the liver was
significantly reduced in KitWsh/Wsh mice, indicating the role of MCs in MDSC recruitment
(Fig. 28B,C). These results were confirmed by in vitro migration assays, in which
MDSCs exhibited a high degree of migration toward MCs (Fig. 28D). This is consistent
with published literature indicating that MDSCs traffic to the liver in tumor models and
that MCs secrete mediators in the liver through the bile(242).
Based on the literature and our previous observations, we hypothesized that upon
migration to the liver, MDSC interaction with MCs culminates into increased cytokine
production that mediates Nb expulsion. Accordingly, MDSCs were compared pre and
post AT to the liver. Intriguingly, we saw an increase in IL-4 and eotaxin, both important
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for Nb clearance from post AT MDSCs (Fig. 29). This suggests that perhaps cross-talk
with MCs in the liver is necessary to enhance MDSC activity.
C. MDSCs express HR1 and HR2.
Given the contribution of histamine to myeloid activity, cell proliferation, and
Th2 skewed immune responses, we examined whether histamine could serve as a
potential mediator in the MC/MDSC cross communication(178,181). Given the recent
reporting of HR1 and HR2 expression on tumor-derived MDSCs, we wanted to
determine whether A10Tg MDSCs also expressed these receptors. Indeed, both GMDSCs and M-MDSCs purified from A10Tg mice expressed HR1 (Fig. 30A). Western
blot not only confirmed HR1 expression but also demonstrated HR2 on MDSCs (Fig.
30B), thus making the contribution of histamine a very likely mediator in the MC/MDSC
interaction.
D. Histamine promotes MDSC survival and proliferation.
Given the expression of HR on MDSCs, we next analyzed the effect of histamine
on MDSCs directly. Accordingly, MDSCs were purified from spleens of A10Tg mice
and cultured in the presence of histamine. Indeed, exposure to histamine prolonged
MDSC survival and induced proliferation in a dose dependent manner, compared to
cRPMI(Fig. 31A,B). The contribution of histamine was confirmed using cetirizine (CT),
an HR1 antagonist. As shown in Fig. 32, CT inhibited histamine-mediated cell
proliferation and cimetidine (CIM), an HR2 antagonist exhibited similar results. The next
logical step in our assays was to determine which fraction of MDSCs was most affected
by histamine. Using proliferation assays, we demonstrate that both M-MDSCs and G72	
  

MDSCs are responsible to the proliferative effects of histamine (Fig. 33). Although both
subsets exhibited increased proliferation in the presence of histamine, M-MDSCs
appeared to be more proliferative.
E. Histamine enhances MDSC enzyme expression.
Given the role of histamine in the immune system, and its ability to induce
MDSC proliferation in vitro, a logical next step was to examine its role in modulating
MDSC enzymatic activity. Accordingly, MDSCs were cultured with histamine or MCs
and subsequently analyzed for expression of Arg 1 and iNOS via quantitative PCR
(qPCR). Indeed, histamine enhanced the expression of both Arg 1 and iNOS (Fig.
34A,B). Intriguingly, in the presence of MCs, only Arg1 was upregulated. We next
wanted to determine if the effects of histamine was subset specific parallel to
proliferation. We compared iNOS and Arg 1 levels in G-MDSC and M-MDSC subsets.
In line with their proliferative response, M-MDSCS exhibited increased Arg1 and iNOS
over the G-MDSCs (Fig. 34C,D). Its important to note that these studies need to be
confirmed but nonetheless provide the platform for a very novel role of histamine for
MDSC activity.
F. MDSC-mediated parasite clearance is abrogated by HR antagonism.
To confirm the effects of histamine on MDSC activity in vivo, we conducted Nb
infection studies with HR1 and HR2 blockade. Accordingly, mice were challenged with
650 L3 Nb and received MDSC i.v. in conjunction with CT. Administration of CT
significantly abrogated the ability of MDSCs to accelerate Nb expulsion (Fig. 35A). This
was correlated with reduced infiltrating MDSCs in the liver (Fig. 35B) and diminished
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phenotypic conversion towards G-MDSCs (Fig. 35C). Given the spectrum of histamine
receptors and our observation of HR1 and HR2 expression on MDSCs, we examined
whether histamine was acting through HR1 independently or congruent with HR2.
Accordingly, we incorporated CIM into our experiments. As shown in Figure 32, CIM
also blocked histamine mediated MDSC proliferation ex vivo. This was confirmed with
in vivo administration of CIM to Nb infected mice also receiving AT of MDSCs. Parallel
to CT, CIM also inhibited the ability of MDSCs to accelerate Nb expulsion, albeit to a
lower degree (Fig. 35D). Administration of CIM also reduced MDSC migration and
phenotype conversion in the liver (Fig. 35E,F). This suggests distinct yet overlapping
roles of histamine mediated via HR1 and HR2 on MDSCs in generating and antiparasitic immune response.
G. HR antagonization inhibits the immunosuppressive potential of MDSCs.
As mentioned earlier, several studies have indicated the contribution of MCs and
histamine to tumor progression(243,244). Accordingly, we were interested in
determining if MDSCs potentially served as bridge linking histamine release and tumor
progression. To do this, we challenged mice with B16 melanoma concomitant with
MDSC administration in the presence or absence of histamine. Intriguingly, mice given
B16, AT of MDSCs, and treated with CIM had significantly reduced colonization to the
lungs compared to mice given B16 and AT of MDSCs without CIM treatment, as
determined by lung weight (Fig. 36). It should be noted that CIM alone had no
significant effect on tumor burden in the absence of AT of MDSCs. This is consistent
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with data showing similar results utilizing a model of murine LLC lung tumor where
CIM treatment resulted in reduced tumor size(180).
H. Histamine induces differential STAT signaling.
Histamine has been shown to induce Stat3 signaling, and the importance of
STAT3 in MDSCs is well documented(35,42,56,73). Furthermore, many groups have
shown that STAT3 and STAT5 are differentially regulated in myeloid cells(245).
Therefore, we wanted to examine which signaling mechanism is triggered by histamine
in MDSCs. To do this, monocytic and granulocytic MDSCs were cultured in the
presence of histamine and proteins isolated for STAT3 and STAT5 proteins. Although
rather preliminary, our data thus far indicate that histamine promotes STAT3 signaling in
M-MDSCs and STAT5 in G-MDSCs (Fig. 37). This is consistent with our observation
that proliferation of M-MDSCs is stimulated by histamine and numerous studies indicate
STAT3 as the main signal transducer of MDSC differentiation and proliferation(94,171).
I. Symptomatic allergic patients have higher circulating MDSCs.
Allergy is a MC-mediated, Th2-dependent immune response. Allergic patients
experiencing symptoms have increased levels of circulating MC derived histamine(246).
To elucidate the translational relevance of our findings and our prediction that allergic
patients will have higher circulating MDSCs, we isolated PBL from symptomatic allergic
patients and non-allergic controls. Human MDSCs are defined as HLA-DRCD33+CD11b+ cells that can also be differentiated into monocytic (CD14+) and
granulocytic (CD15+) subsets(132). In accordance with our prediction, allergic patients
exhibited a larger percentage of circulating MDSCs compared to non-allergic control
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patients (Fig. 38A,B). These findings require analysis of additional patient samples but
nonetheless indicate a role of histamine in MDSC subset accumulation.
J. Histamine promotes the ex vivo survival of MDSCs generated in stage1 primary breast
cancer.
Given the ability of histamine to prolong life-span of murine MDSCs, we wanted
to examine if the same would hold true for human MDSCs. To do this, we utilized
previously purified and cryopreserved samples of MDSCs from a stage1 primary breast
cancer patient. In line with published observations, these human MDSCs did not survive
in cultured medium in the 48hr window. However, we observed a steady population and
enhanced life span of MDSCs even at 48hrs in the presence of histamine (Fig. 39). While
quite preliminary, this observation has important implications for the utilization of
histamine to prolong MDSC survival in ex vivo studies.

76	
  

DISCUSSION
I. ADAM10 is required for appropriate hematopoietic cell development and
differentiation.
Because ADAM10-mediated S2 cleavage is required for the initiation of the
canonical Notch signaling pathway, we hypothesized that ADAM10 serves as a critical
regulator in the differentiation of early hematopoietic progenitors. Our experimental
observations demonstrate that ADAM10 overexpression attenuates the development of
thymocytes, abrogates B2 cell development, and promotes expansion of functional
MDSCs via a cell-intrinsic mechanism. Furthermore, our studies indicate that S2 and S3
cleavage products of Notch differentially regulate hematopoietic cell fate determination.
Although effects of Notch signaling in B cell and T cell lineage commitment has
been extensively described, the effect of ADAM10 activity in cell differentiation and
early B lineage commitment was previously uncharacterized(228). Here, we demonstrate
that overexpression of ADAM10 in early lymphoid precursors prevented B2 cell
commitment from CLPs. Interestingly, this was specific to BM-derived B2 cells, while
development of B1 cells which reside in peritoneal and pleural cavities was not affected,
presumably due to the unique developmental pathways of B1 and B2 cells. B1 cells
largely originate from fetal liver and the molecular pathways that direct B1 cell
development are quite distinct from those critical to B2 cell commitment(247). The
sparing of B1 cell development in A10Tg mice is consistent with the finding that B cellspecific deletion of ADAM10 and other regulators of Notch signaling do not affect B1
cell development(13,28,33). Given the lack of B2 cells in A10Tg mice and that we only
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observed B2 cell development from A10Tg HSCs upon ADAM10 inhibition in OP9
cultures, we are confident that ADAM10 is heavily involved in B2 lineage commitment.
Although ADAM10 may influence B cell development by cleaving multiple substrates,
its prominent role in hematopoiesis is the regulation of Notch signaling. In fact,
ADAM10 inhibition in OP9-DL1 cultures prevented Notch-dependent T cell
development while simultaneously promoting B cell development. This finding is
consistent with the report demonstrating that deletion of Notch1 from CLPs results in the
development of B cells in the thymus(21). However, we cannot rule out the possibility
that other ADAM10 substrates could potentially contribute to the altered hematopoiesis
observed in A10Tg mice.
The development of thymocytes from BM precursors in A10Tg mice was delayed
in our studies. This was demonstrated by diminished thymus size, a relative inability of
A10Tg thymocyte precursors to develop in mixed BM chimeras, and delayed
development of A10Tg T cells in OP9-DL1 cultures. The data are consistent with ligand
independent cleavage of Notch S2 as a consequence of increased ADAM10 activity. It is
possible that, in the absence of ligand, γ-secretase complex is not recruited to the cell
membrane and/or becomes saturated, leading to less efficient S3 cleavage and less T cell
development. Given the high ligand expression levels in OP9-DL1 cells, we anticipated
proper T cell differentiation in A10Tg HSCs as the S2 product would not be in excess.
Indeed, T cell development in A10Tg HSCs was comparable to LM HSCs. It should be
noted that because A10Tg HSCs are not different from LM, this cannot be attributed to
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seeding of different progenitor populations on OP9s but rather excessive ADAM10
causing ligand-independent S2 cleavage.
While the effects of Notch signaling in B and T cell lineage commitment have
been thoroughly described, its role in myeloid development is controversial(248).
Kawamata et al. reported that enforced expression of NICD or Notch target genes, Hes 1
or Hes5, caused non-cell autonomous expansion of Mac-1/CD11b+Gr-1+ myeloid cells
from BM precursor cells(31,249). This is consistent with our model system of increased
CD11b+Gr-1+ myeloid cells in A10Tg MDSCs. Moreover, the elevated levels of CMPs in
A10Tg BM and the lack of ADAM10 overexpression by CMPs, CD11b+Gr-1+ BM cells,
and splenic MDSCs indicate that HSC development is altered at an early stage prior to
mature cell lineage commitment. Additionally, mixed BM chimeras revealed that
myeloid expansion in A10Tg mice occurs by a cell autonomous mechanism.
Furthermore, complete γ-secretase inhibition of LM and A10Tg HSCs on OP9-DL1
cultures resulted in myeloid expansion. This is in agreement with other studies that have
shown γ-secretase blockade to result in accumulation of the S2 product, that could direct
myeloid development(16,20). Indeed, diminished presenilin (PS) dependent γ-secretase
activity in PS1+/-PS2-/- mice results in myeloproliferative disease, characterized by
accumulation of Mac-1/CD11b+Gr-l+ cells, causing splenomegaly(40). Thus, ligand
independent S2 Notch cleavage and ADAM10 overexpression may direct myeloid
development by independent mechanisms. Nevertheless, these studies indicate that
perturbation of Notch signaling in HSC development can induce myeloid expansion.
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The classical model of hematopoiesis describes the initial dichotomous
differentiation of HSCs into CLPs or CMPs. However, this has been challenged by
observations in which lymphoid progenitors retain myeloid potential(250-254). For this
reason, a myeloid-based model of HSC development is beginning to emerge(34,41). In
A10Tg mice, the moderate effects on thymocyte development in combination with the
more pronounced effects on B lineage commitment and myeloid expansion indicate that
B2 cells and expanded myeloid cells develop from common progenitor(s), whereas
thymocytes may develop from a unique precursor. It should be noted that upon lineage
depletion, comparable BM cell numbers were recovered from both A10Tg and LM mice.
Therefore, the percentage of ETPs obtained is reflective of absolute numbers of
thymocyte precursors in the BM. Although peripheral T cell levels are comparable, the
observed reduction in ETPs is nonetheless very intriguing and will require further study.
Clearly the differential effects of ADAM10 overexpression on lymphocyte and
myeloid development are in congruence with the myeloid-based model of hematopoiesis.
The shift in favor of CMPs could explain the robust accumulation of MDSCs in the
periphery. Further analysis is required to ascertain whether the lower levels of MEPs and
GMPs are a result of a halt in development at the CMP stage, or simply due to the high
level of CMP formation. Additionally, because CMPs have been shown to retain
erythromyeloid potential, it is not surprising that despite the decreased MEP and GMP
compartments, erythropoieis remains unaffected.
Based on our data, we have formulated a model through which Notch cleavage
mediates cell fate determination (Figure 40). In the presence of ligand, the Notch
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receptor undergoes cleavage at both S2 and S3 sites, resulting in two products and
ultimately promoting T cell development. In the absence of Notch ligand or in the case of
blocked S2 cleavage, the Notch receptor remains intact and B cell development results.
However, S2 cleavage without S3 cleavage, as observed during ADAM10
overexpression, induces myelopoiesis and delayed T cell development. All of the
aforementioned scenarios are predicted to occur under basal physiologic conditions in
WT mice and thus, cell differentiation is regulated by the S2/S3 product ratio and the
abundance of cleaved Notch products. This concept is further supported by our S2/S3
inhibitor assays in the OP9 culture system. Although further studies are needed to
identify the mechanism at a transcriptional level, it appears that three branch points exist
in the Notch signaling pathway. The first pathway occurs when an intact Notch receptor
is present, resulting in B cell differentiation. This case occurs when either the S2
cleavage site is blocked or in the absence of ligand in WT animals. The second pathway
is determined by ligand-independent S2 cleavage, which ultimately results in myeloid
expansion, whereas the third case is determined by cleavage at both S2 and S3
sites, affording T cells. The A10Tg animal is representative of the second case, in which
ADAM10 overexpression results in excessive ligand-independent Notch cleavage
leading to extensive myeloid development. Furthermore, the delayed T cell maturation in
both the A10Tg animals and in OP9-DL1 cell cultures can be attributed to limited Notch
ligand engagement and cleavage.
The differential effect of S2 and S3 blockade on WT Notch signaling has
significant implications for the treatment of Notch-related diseases. Many reports have
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proposed the use of GSIs for the treatment of T-ALL and B cell lymphoma, however; our
findings indicate that GSI treatment could cause MDSC expansion that would ultimately
induce immunosuppression and enhance tumor growth(23,255). Thus, studies of GSI
treatment in mice and clinical trials should include careful monitoring of the myeloid
compartment. Our studies suggest that the addition of ADAM10 inhibitors to GSI
treatment may be a more advantageous strategy.
II. A10Tg MDSCs are functionally analogous to tumor-derived MDSCs and require
MCs for their activity.
Despite the profound increase in myeloid precursors, A10Tg mice do not develop
any confounding pathologies such as chronic myelogenous leukemia (CML) or
accelerated tumor development. Therefore, A10Tg mice afford a unique tool to
characterize the immunomodulatory potential of MDSCs in an environment devoid of
established tumor and tumor-derived factors. While this property makes our model ideal
for the study of neoplasia, we, by extension, demonstrate that A10Tg mice are likewise a
viable system to elucidate disease states in which MDSCs are not detrimental to the host.
Here we report that 1) MDSCs generated in a tumor free environment, at least with this
A10Tg model, are functionally and phenotypically analogous to tumor derived MDSCs.
2) MDSC-mediated augmentation of tumor growth is enhanced by mast cells (MCs). 3)
MDSCs exert an immune enhancing potential in promoting a robust anti-helminth
immunity that is also largely dependent upon interaction with MCs. 4) MC/MDSC
interaction augments cytokine production by both cells, promoting a Th2 skewed
immune response that is harmful in neoplastic progression but beneficial in parasitic
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infections. Our studies demonstrate that MDSCs possess a duality in terms of their
function, contingent upon the pathophysiological context to which they are subjected.
MDSCs derived from A10Tg mice suppress T cell proliferation under both
polyclonal and antigen specific stimulation to a degree comparable to tumor-derived
MDSCs. A10Tg MDSCs also exhibit comparable Arg1 and iNOS levels to tumorassociated MDSCs. Furthermore, the dramatic increase in metastatic progression and
resistance to AIT in A10Tg mice compared to LM controls demonstrates that A10Tg
MDSCs contribute to tumor-associated immune suppression. In fact, the increased
sensitivity of T cells to MDSCs in A10Tgs illustrates that the in vivo presence of MDSCs
is sufficient to diminish T cell responses, even in a tumor-free environment. This effect
can be rescued upon MDSC depletion, which is evidenced through the ability of A10Tg
T cells to halt B16 progression to a similar degree as in LM with GEM treatment. This
observation also indicates that MDSC-mediated T cell suppression is not permanent.
Even more convincing is the complete regression of the B16 melanoma observed
following tri-therapy (GEM + CYP + AIT). These collective observations clearly
delineate that the increased metastatic progression in A10Tg mice is a consequence of
ADAM10-mediated expansion of functional MDSCs rather than impaired T cell
response. It is important to note that we did not observe significant MDSC accumulation
in WT mice upon B16 challenge. This makes the B16 model ideal to state the
consequence of MDSC administration on B16 progression.
MDSCs are widely recognized for their negative role in the context of neoplasia
and antineoplastic therapy. Nonetheless, eradication of these cells may have detrimental
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consequences for the host. In fact, studies suggest a beneficial role of MDSCs in graftversus-host disease (GVHD), autoimmunity, bacterial infections, and more recently,
MDSC driven cancer vaccines(55,130,189). In the case of parasitic infections, MDSCs
have been reported to accumulate but their effect on the immune response remained
unclear(256). Therefore, we utilized A10Tg mice and a model of helminth infection, N.
brasiliensis to answer the following questions: 1) Whether MDSCs could differentially
regulate the immune response depending on the Th1 or Th2 inducing disease state? 2)
Whether MCs only function in recruiting MDSCs or if they could actually affect the
immunoregulatory activity of MDSCs?
Our results were quite exciting and provide novel insight into the role of MDSCs
in regulating the immune response in the context of interaction with MCs and disease
progression. The results indicate that MDSCs promote robust anti-helminth immunity.
A10Tg mice had a dramatically increased rate of worm expulsion as compared to LM
controls. This resistance occurs quite early, as lungworm counts at day 2-post infection
were significantly lower in A10Tgs. The restoration to LM susceptibility upon GEM
treatment in A10Tg mice coupled with increased resistance in LM animals with AT of
MDSCs strongly indicates the involvement of MDSCs. This finding was further
solidified by AT of MDSC subsets, which demonstrated that the enhanced anti-helminth
immunity was indeed MDSC driven, and that the granulocytic Ly6G+ and not the
monocytic Ly6C+ population of MDSCs enhanced anti-Nb immunity.
Physiologically, the observed anti-helminth immune response in A10Tg mice was
accompanied by an upregulation of multiple Th2 cytokines that are critical mediators of
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anti-Nb immunity. These observations highlight a mechanistic foundation for MDSCmediated anti-helminth immunity, namely increased production of Th2 associated
cytokines. It is possible that MDSCs may not only secrete Th2 polarizing cytokines, but
also stimulate their production by other immune cell populations. The most logical
candidate for this relationship comprises MDSCs and MCs. Within the context of
helminth infections, IgE mediated MC degranulation initiates cytokine production,
ultimately accelerating worm expulsion(237). Given that MCs recruit MDSCs and they
mediate parasite clearance, we tested whether this interaction was also critical in the
immune response. The challenge of MC deficient Kit

Wsh/Wsh

mice with Nb concomitant

with MDSC AT provided novel insight. The data showed that while MDSCs can
accelerate parasite clearance, they require MCs for their activity. This is likely to be
cytokine mediated. In fact, in vitro analysis of MC/MDSC co-cultures demonstrate a
synergistic increase in measured cytokines; especially IL-13 which is critical for
helminth expulsion(257).
Given our observation of MDSC’s dependency on MCs in anti-Nb immunity,
increased cytokine production in MC/MDSC co-culture, and recent data of tumor
development indicating that MCs are capable of mobilizing MDSC populations, we
tested the contribution of MC/MDSC crosstalk to metastasis. Prior to our investigations,
it was unclear if once recruited by MCs, MDSCs would then act independently or require
further interaction with MCs. Therefore MC deficient KitWsh/Wsh WT controls were
utilized to examine MDSC-mediated B16 progression in the presence or absence of MCs.
While we agreed with published literature that B16 colonization to the lungs would be
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reduced in MC deficient mice, we nonetheless expected increased colonization upon
MDSC AT (241). However, much to our surprise, the presence of MDSCs had little
effect on tumor growth in these MC deficient hosts, suggesting the requirement of MCs
for MDSC’s immunosuppressive tumor-promoting activity. This finding was quite
exciting and prompted us to further confirm and examine the crosstalk between MCs and
MDSCs.
III. Histamine is a key player in the MC/MDSC interaction.
While our results were quite intriguing, we needed to first ensure that our
observations were not unique to MDSCs isolated from A10Tg mice and the KitWsh/Wsh
MC deficient model. To this end, we employed an additional model of MC deficiency as
well as conducted a parallel MDSC AT into Nb infected mice with MDSCs generated in
WT LLC bearing mice. Our assays have demonstrated that regardless of source, MDSCs
exert an immunoregulatory role depending on disease state and absolutely require MCs.
By extension, we have also determined histamine to be an important mediator in the
observed MC/MDSC interaction.
The ability of MDSCs derived from LLC bearing mice to clear Nb, clearly
demonstrates that enhanced parasite clearance is not unique to A10Tg animals. The
observation that MDSCs also failed to promote Nb clearance in Cpa3-Cre; Mcl-1fl/fl MC
deficient mice but regained activity in MC reconstituted KitWsh/Wsh , clearly emphasize
that MDSCs depend on MCs to exert their effects. Furthermore, AT assays of labeled
MDSCs in these model systems allowed us to examine the trafficking pattern of MDSCs
in relation to MCs. Previous literature indicates that during tumor progression, MDSCs
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traffic and accumulate in the liver, where they inhibit Kupffer cells and T cells to dampen
anti-tumor immune responses(221,258,259). Moreover, hepatic MDSCs have been
shown to produce a wide array of proinflammatory and regulatory cytokines and
chemokines in response to tumor challenge(221). Indeed, in our Nb infection model,
MDSCs preferentially migrate to the liver. Thus, it is possible that in the liver, MDSC
interact with hepatic MCs and become further activated. In fact, it was reported that
hepatic MCs release histamine and other mediators through the portal bile ducts and into
the bile(242), which can have significant implications for parasite load in the gut.
Interestingly, we observed a significant increase in c-kit+ cells in the liver after Nb
infection. This highlights the fact that the liver may be an important site for MC
accumulation and activity in Nb infection. The interaction between MCs and MDSCs in
the liver would presumably lead to increased cytokine production and soluble mediator
release such as histamine that would enhance MDSC activity and subsequent Nb
expulsion (Fig. 41). This could provide a potential explanation for our observations that
in the absence of MCs, MDSC migration to the liver and parasite expulsion are
significantly reduced.
MCs and histamine have been shown to play an important role in parasitic
clearance. Livestock animals with increased numbers of MCs and concentrations of
histamine are positively correlated with natural helminth resistance or tolerance(260).
Acting in conjunction with IL-4 and IL-13, histamine has been associated with increased
smooth muscle cell contractions to enhance the ‘sweep’ portion of the ‘weep and sweep’

87	
  

method of parasitic clearance(261,262). Our studies also demonstrate that histamine
further promotes parasite expulsion through MDSC activation and proliferation.
We show that MDSCs express both HR1 and HR2, which are classically linked to
the immune system. The addition of histamine to MDSCs protected against cell death
and increased cellular proliferation. Interestingly, this was more prominent in M-MDSCs
than in G-MDSCs. This could be attributed to the fact that granulocytes have a shortened
half-life as compared to monocytes in culture(150,172). Furthermore, histamine
enhanced Arg1 and iNOS expression by MDSCs. Interestingly, uncrosslinked MCs cocultured with MDSCs upregulated Arg1 but not iNOS expression. This could indicate
that uncrosslinked MCs do not release histamine sufficiently to induce iNOS activation
of MDSCs, demonstrating that MC degranulation is needed for optimal MDSC
activation. These studies are supported by a recent publication in which histamine
blockade with CIM increased MDSC apoptosis, reduced Arg1 and iNOS enzyme
expression, and decreased tumor burden(180). More recently, it was shown that MDSCs
are also capable of synthesizing low levels of histamine, which directed their
differentiation and survival (181).
The interaction between histamine and MDSCs became more apparent upon
histamine receptor blockade in our in vivo model systems of disease progression and in
vitro mechanistic assays. Administration of HR1 and HR2 antagonists in mice challenged
with Nb and given MDSC AT recapitulated our findings in MC deficient mice. This
suggests that histamine signaling is the bridge between MCs and MDSCs. CT has been
previously shown to affect migration of cells of myeloid lineage(263,264). This may be
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the reason that MDSC trafficking to the liver is reduced but still does not explain why GMDSCs and not M-MDSCs were reduced. HR2 antagonists have been shown to alter T
cell production of IL-14, IL-5 and IL-13, all of which are involved in appropriate antihelminth immunity(257,265,266). Although preliminary, our findings also indicate that
hepatic MDSCs produce IL-4 after Nb infection, indicating that perhaps CIM works by
reducing MDSC cytokine production involved in parasite clearance rather than their
migration.
One of the most important signaling pathways for MDSC accumulation has been
STAT3(245,267). Interestingly, we found that histamine induced differential STAT
signaling; predominantly STAT3 in monocytic MDSCs and STAT5 in granulocytic
MDSCs. This observation is in line with previously published data indicating that the
upregulation of STAT3 is associated with increased cellular proliferation and enzymatic
activity of MDSCs(42,94,171). Because neutrophils have a short half-life, it was not
surprising that the neutrophil-like G-MDSCs exhibited a lower degree of proliferation
and STAT3 signaling as compared to M-MDSCs(150). While the MC/MDSC interaction
is multifarious, we propose that MC-derived histamine drives the distinct MDSC
subpopulations to differential STAT signaling, inducing distinct phenotypic activation
that further directs MC activity.
Upregulation of MDSCs in patient peripheral blood has been indicated in many
cancers and suggested as a marker of poor prognosis(268-270). The link between
inflammation and cancer has been heavily studied in the last decade but remains elusive
(271-273). We suggest that MC/MDSC interactions can potentially contribute to this
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phenomenon. To our knowledge, we are the first to report MDSC expansion in
symptomatic allergic patients; especially G-MDSCs. The link between histamine and
human MDSCs is further supported by increased survival of human MDSCs cultured
with histamine.
Collectively, our results demonstrate that MCs are required for MDSC motility
and activity. Given our findings and current literature on MDSCs, we have generated a
model of this interaction (Fig. 41). We hypothesize that in the liver, as well as other sites
of immune response, resident MCs attract MDSCs and activate them via histamine
release. Upon activation, MDSCs secrete Th2 cytokines, most notably IL-4 and IL-13,
which promote Th2 differentiation, along with IL-6 and TGF-β that chemoattract MCs.
In this context, T cells not only contribute to the pool of IL-4 and IL-13 but also increase
IgE synthesis by B cells. IgE in turn further activates MCs. These events afford a selfsustaining and synergistic cycle of MC/MDSC activation that results in increased
survival, proliferation, and activation. This ultimately leads to a Th2 skewed immune
response that is detrimental in neoplasia but beneficial for helminth expulsion. This
interaction has important implications for regulation of MDSC activity via antihistamines
and MC stabilizing agents for disease states in which the accumulation of MDSCs is
detrimental to the host.
IV. Conclusions and Significance.
The goal of this dissertation project was to determine the physiologic significance
of ADAM10-mediated Notch cleavage in hematopoiesis. To this end, we generated mice
with increased ADAM10 expression in early progenitor cells. Consequently, A10Tg
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mice exhibit abrogated B cell development, delayed T cell maturation, and increased
immature myeloid cells. As a result, these mice have allowed our laboratory to make
significant contributions to the literature in the context of hematopoietic cell
development, neoplastic progression, and anti-parasite immunity.
Our data demonstrate that the proteolytic activity of ADAM10 regulates the
lineage commitment of B2 cells and the expansion of functional MDSCs in a cellintrinsic manner. Moreover, A10Tg mice provide a model system to further examine
MDSC expansion and MDSC-mediated immune suppression in the absence of
confounding tumor-derived factors. Consequently, we have shown that increased
MDSCs render A10Tgs more susceptible to tumor metastasis but resistant to helminth
infection. MCs are required for both the observed immunosuppressive and
immunoenhancing properties of MDSCs. MDSCs traffic to MCs, affording a synergistic
Th2 skewed immune response. While undesirable in the context of neoplasia, the
observed response is ideal in parasitic (at least with respect to helminth) infections. This
augmentation of MDSC activity in the presence of MCs was further evaluated using the
mast cell derived factor, histamine. We demonstrate that MDSCs express HR1 and HR2
with increased expression on M-MDSCs. Histamine promotes MDSC activity and
proliferation, particularly in M-MDSCs. Furthermore, HR 1 and HR2 antagonization
abrogate MDSC activity in our murine model of parasitic infection as well as tumor
progression.
Unresolved inflammation increases myelopoiesis, resulting in premature bone
marrow release of a heterogeneous group of mononuclear (CD11b+Ly6Chigh) and
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polymorphonuclear (CD11b+Ly6Ghigh) cells, known as myeloid derived suppressor cells
(MDSCs). MDSCs have been associated with increased risk of metastatic progression
and poor therapeutic response in cancer patients. We have recently begun to demonstrate
an important role for Mast Cells (MCs) and MC-derived histamine in this MDSCmediated immune suppression. Furthermore, the data presented here suggest that MDSCs
may serve as the bridge between controversial correlation of allergic inflammation and
tumor progression. Our data underscore a previously unappreciated functional duality for
MDSCs, ranging from immunosuppressive to immunosupportive contingent upon
physiological context. These studies have important implications for enhancing tumor
rejection by the modulation of MDSC activity and application of pharmacologic
inhibitors of MC function in new therapeutic strategies for cancer treatment.
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Figure 1. ADAM10-mediated Notch signaling. At the surface, Notch is expressed as an
integral membrane protein, consisting of both extracellular (NEXT) and intracellular
domains (NICD). Once engaged with its ligand (Delta-Like 1), the extracellular domain
undergoes an ADAM10-mediated cleavage at site 2 (S2). This event generates a
substrate for γ-secretase complex to perform a final cleavage of Notch at site 3 (S3),
releasing the transcriptionally active NICD that subsequently translocates to the nucleus
to induce downstream signaling pathways.

93	
  

Figure 2. Putative role of ADAM10 in hematopoietic cell differentiation. Subsequent
to ligand engagement and appropriate cleavage by ADAM10 and γ-secretase, Notch
intracellular domain (NICD) translocates to the nucleus and facilitates transcriptional
upregulation of PU.1, mediating differentiation between MDSCs and B cells. IRF-8
serves as a positive EBF/E2A transcription system, which regulates B cell development.
IRF-8 also acts as negative modulator of PU.1, alleviating suppression of the PAX5
transcription factor required for B-cell development. Therefore, the expression of IRF-8
and PU.1 transcription factors as well as Notch signaling regulates MDSC development.
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Figure 3. MDSC induction and function. Various hematopoietic cytokines such as
GM-CSF and VEGF promote the premature release of MDSCs from the BM. Once
recruited to the site of immune response, MDSCs impair both arms of the immune
response. In particular, they inhibit T cell activation, induce T-regulatory cells, limit B
cell antibody production, restrict DC maturation, promote the activation of
immunosuppressive Type 2 macrophages, and impair appropriate NK activity.
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Figure 4. Cytokine mediated MDSC generation. Heterogeneous MDSC generation is a
consequence of numerous cytokines. However, the development of granulocytic or
monocytic MDSCs is unique to certain cytokines; GMCSF and IL-4 promote M-MDSCs
while GCSF and IL-1β promote G-MDSCs.
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Figure 5. MDSC subset identification based upon protein expression and function.
MDSCs can further be delineated into granulocytic or monocytic subpopulations based
upon surface marker expression, cytokine production, and function.
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Figure 6. MDSC accumulation in neoplasia is type specific. Granulocytic or
monocytic MDSC accumulation is unique to anatomical location of neoplastic
progression. Overall, G-MDSCs tend to comprise most cancers, particularly solid tumors.
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Figure 7. Generation of ADAM10 transgenic mice. (A) Schematic of the 7.5-kb XhoI
injection fragment containing the murine ADAM10-HA cDNA and the murine H-2Kb
promoter and IgH enhancer regulatory elements. (B) Southern blot analysis of genomic
tail DNA from both founders (F) and their F2 progeny (F2a and F2b) digested with AccI
and electrophoresed on a 0.9% agarose gel along with 1 kb DNA Ladder markers (M).
The injection fragment shown in (A) was used as both probe and copy number control
(5x and 25x). A10Tg lines 240 and 258 possess greater than 25 copies of the transgene,
generating 1797 bp junction fragments (1612 bp + 185 bp) indicative of head-to-tail
arrays, as well as 1270 bp and 4464 bp internal fragments. The founder of line 258
appears to be mosaic, identifiable as a transgenic by PCR only.
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Figure 8. ADAM10 Overexpression blocks B2 B cell development. (A) Flow
cytometric analysis of pro/pre B cells (B220+IgM) and immature B cells (B220hiIgM+) in
BM of littermate (LM) and A10Tg progeny. (B) ADAM10 surface expression by
B220+IgM cells and B220IgM cells. Dot plots and histograms in (A,B) are representative
of 6 independent experiments. (C) Western blot analysis of ADAM10 and β-actin protein
levels in whole cell lysates of BM cells from indicated mice; ADAM10 pro-form (80
kDa) and ADAM10 mature form (60 kDa), representative of 3 independent experiments.
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Figure 9. ADAM10 overexpression does not affect B1 B cell development but
suppresses

thymocyte progenitors. (A,B) Flow cytometric analysis of (A) T cells

(CD3+) and B cells (B220+) in spleen (SPL); and (B) B cell subsets in peritoneal fluid.
Lower two panels are gated on B220+ cells in upper histograms. B2 cells:
B220hiCD11b-CD5-, B1a cells: B220intCD11b+CD5+, B1b cells: B220intCD11b+CD5-.
(C) Representative thymi from indicated mice. Bone Marrow cells were analyzed for LinCD25-CD44+c-kit+ early thymocyte progenitors (ETPs). Lineage cocktail includes B220,
Ter-119, CD11b, Gr-1, CD3, CD4, CD8. (D) Amount of thymocyte subsets and CD3+ T
cells in the spleen and PLN; n=4, mean ± SEM, DN: CD4-CD8-, DP: CD4+CD8+, CD4:
CD4+CD8-, CD8: CD4-CD8+. Dot plots and histograms are representative of 6 (A), 4(B),
3(C) independent experiments. Numbers on plots indicated percent of gated cells within
box. * p<0.05
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Figure 10. ADAM10 overexpression causes the expansion of myeloid-derived
suppressor cells. (A) Representative spleens and average spleen weight of indicated
mice, n=4, mean ± SEM. Flow cytometric analysis of (B) forward scatter (FS) vs. side
scatter (SS) of splenocytes, the percentage of (C) CD11b+Gr-1+ MDSCs present in the
bone marrow (BM), PBL, and spleen (SPL), and the percentage of (E,F) CD11b+Ly6-G+
and CD11b+Ly6-G- MDSCs in (E) PBL and (F) spleen of indicated mice. (D) 40X and
100X photomicrographs of sorted CD11b+Gr-1+ splenocytes from A10Tg mice. Flow
cytometry plots and photomicrographs are representative of 4 independent experiments.
Numbers on plots indicate the percentage of cells in the UR (C) and UR,LR quadrants
(E) and (F).
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Figure 11. A10Tg B220+CD19+ bone marrow cells express myeloid markers. (A,B)
Flow cytometric analysis of (A) CD19 and B220 labeled cells and (B) Gr-1 and CD11b
labeled cells, gated on B220+CD19+ cells shown in (A). (C) ADAM10 surface expression
by hematopoietic stem cells (HSCs), common myeloid progenitors (CMPs), and common
lymphoid progenitors (CLPs) from BM. Numbers on dot plots and histograms indicate
percent of gated cells shown in box or linear markers, respectively; representative of 3
independent experiments.
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Figure 12. Overexpression of ADAM10 alters hematopoiesis prior to CLP
commitment to the B cell lineage. Flow cytometric analysis of (A) Lineage negative
(Lin-) and CD19 labeled BM cells, (B) B220 and IL-7 receptor (IL7R) expression by LinCD19- gated cells, (C,D) c-kit and sca-1 expression of (C) Lin-CD19-B220-IL7R- cells
and (D)Lin-CD19-B220-IL7R+ cells. (E,F) Expression of Ly6D by (E) CLPs of LM and
A10Tg mice, and (F) Lin-CD19-B220+ BM cells from LM mice. Numbers on dot plots
and histograms indicate the percentage of BM cells (percentage of gated cells) in box or
linear marker, respectively. The cell lineage includes Ter-119, CD11b, Gr-1, and CD3ε
positive cells. Plots are representative of 3 independent experiments. Lin- populations are
defined as follows, HSCs: Lin-CD19-B220-IL7R-c-kit+sca-1hi; CMPs: Lin-CD19-B220IL7R-c-kit+sca-1-, CLPs: Lin-CD19-B220-IL7R+c-kitintsca-1int.
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Figure 13. ADAM10 overexpression dysregulates development of myeloid and T cell
progenitors, but not LSK subsets. Flow cytometric analysis of (A) Lin- bone marrow
cells. (B) CD34 and FcgRII/III expression on CMP gate from (A). (C) CD34 and Flt3
expression in the Lineage-Sca-1+c-kit+ (LSK) gated cells from (A). (D) Bone marrow
cells were also analyzed for early thymocyte progenitors (ETPs). For D, CD25 was
added to the lineage negative cocktail. Numbers on dot plots indicate the percentage of
gated BM cells. Cell lineage cocktail includes B220, Ter-119, CD11b, Gr-1, and CD3
positive cells. Plots are representative of 3 independent experiments. LSKs were gated as
Lin-sca-1hic-kit+ and subdivided to Long-term Hematopoietic Stem Cells (LT-HSCs):
CD34-Flt3-, Short-term Hematopoietic Stem Cells ST-HSCs: CD34+Flt3-, and
Multipotent Progenitors (MPPs): CD34+Flt3+. The c-kit+ myeloid cells were gated and
105	
  

defined as Common Myeloid Progenitors (CMPs): CD34+FcgRII/IIIlo, GranulocyteMacrophage Progenitors (GMPs): CD34+FcgRII/IIIhi, and Megakaryocyte-Erythroid
Progenitors (MEPs): CD34-FcgRII/IIIlo.
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Figure 14. Altered hematopoiesis is unique to A10Tg HSCs. Flow cytometric analysis
of BM and PBL cells gated on (A) CD45.2+ cells developing from adoptively transferred
A10Tg Lin- BM cells in CD45.1+ congenic WT mice, and cells gated on (B) CD45.1+
cells developing from adoptively transferred WT Lin- BM cells in A10Tg mice, 6 weeks
after transfer. BM and PBL plots are representative of 2 and 4 independent experiments,
respectively. Numbers on plots indicate the percentage of gated cells within box.
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Figure 15. ADAM10 alters hematopoiesis by a cell-autonomous intrinsic
mechanism. Flow cytometric analysis of (A) myeloid and (B) lymphocyte differentiation
in mixed BM chimeras generated as described in the Methods 42 days after cell transfer.
CD45.1+ and CD45.2+ gated cells differentiated from WT and A10Tg LSK BM,
respectively. Data are representative of 3 independent experiments, except PBL data is
representative of 6 independent experiments; numbers on dot plots indicate the percent of
CD45.1 or CD45.2 gated cells within boxes.
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Figure 16. Inhibition of γ-secretase or ADAM10 activity prevents Notch-dependent
T cell development. (A,B) Flow cytometric analysis of differentiated HSCs co-cultured
with (A) OP9-GFP or (B) OP9-DL1 stromal cells for 8, 17, and 29 days; representative
of 4 independent experiments. (C) T cell development of HSCs co-cultured with OP9DL1 cells in the presence of a γ-secretase inhibitor, Compound E, or an ADAM10
inhibitor, GI254023X; representative of 2 independent experiments.

110	
  

Figure 17. γ-secretase and ADAM10 inhibition have differential effects on Notchmediated HSC differentiation. Flow cytometric analysis of HSC differentiation after 29
days of HSC co-culture with (A) OP9-DL1 or (B) OP9-GFP stromal cells as described in
the Methods. Compound E, GI254023X, or control DMSO was added to media to inhibit
γ-secretase or ADAM10 activity, respectively. DMSO-treated plots are representative of
4 independent experiments; plots of inhibitor-treated cultures are representative of 2
independent experiments. Numbers on plots indicate the percentage of gated cells within
boxes.
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Figure 18. MDSCs from A10Tg mice are phenotypically and
functionally analogous to tumor-derived MDSCs. (A) Proliferation of purified WT
and A10Tg splenic T cells in the presence of increasing amounts of A10Tg CD11b+
MDSCs (Ly6G+,Ly6G-, or Gr-1+); stimulated with immobilized anti-CD3 and soluble
anti-CD28. (C) Purified pmel-1 TCR transgenic splenocytes were cultured in the
presence of increasing A10Tg MDSC subsets and stimulated with gp100 peptide. (D)
Tumor derived MDSCs were purified from LLC bearing mice and used in suppression
assays with Pmel1 splenocytes at increasing ratios (T cells or splenocytes: MDSCs,
*p<0.05), stimulated with gp100 peptide. (E) Cell surface expression of L-selectin
112	
  

(CD62L) by CD4+ and CD8+ (F) gated T cells from peripheral lymph nodes (PLNs).
Lysates of MDSCs derived from Lewis Lung Carcinoma bearing WT hosts and A10Tg
MDSCs were analyzed for the activity of (G) Arginase by urea production and (H) Nitric
oxide by Greiss Reagent. The data is representative of at least three independent
experiments with splenocytes from three or more mice.
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Figure 19. MDSC depletion restores the anti-tumor response and prevents
metastatic progression of B16 melanoma in A10Tg mice. (A) Number of lung
metastases in LM and A10Tg animals two weeks after B16 melanoma challenge i.v. with
or without adoptive immunotherapy (AIT) as described in Methods. Number of lung
metastases of LM (B) or A10Tg (C) mice challenged with B16 and treated as in A with
the addition of cyclophosphamide (CYP) and gemcitabine (GEM). (D) Representative
lungs of LM and A10Tg mice with AIT with and without CYP and GEM. *p<0.05 in
comparison to respective untreated controls.
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Figure 20. Gemcitabine selectively depletes MDSCs, which allows for effective AIT
with tumor specific T cells. (A) FACS analysis of peripheral blood leukocyte levels in
A10Tg mice following i.p. injections with gemcitabine (upward arrow) every five days
for three weeks, *p<0.05. (B) Number of B16 lung metastases in WT (white bar) and
A10Tg mice (gray bar) treated with AIT comprised of pmel-1 transgenic T cells and
chemotherapeutics as described in Methods. *p<0.05 in comparison to respective
untreated controls and #p<0.05 in comparison to respective AIT+ CYP treatment.
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Figure 21. M-MDSCs promote B16 melanoma colonization to the lungs.
Quantification of B16 lung metastasis in WT C57/BL6 mice with AT of either GMDSCs (CD11b+Ly6G+) or M-MDSCs (CD11b+Ly6C+) purified based upon surface
maker expression, as described in Methods. More than five mice were used per group in
three independent experiments. *p<0.05 in comparison to respective G-MDSC group.
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Figure 22. A10Tg mice are resistant to Nb infection. (A) Eggs/gram feces were
determined at indicated times in WT and A10Tg mice as well as A10Tgs treated with
GEM or WT with adoptive transfer (AT) of MDSCs upon infection with 650 Nb L3
worms. (B) WT and A10Tg mice were examined on day seven for adult worm recovery
as described in Methods. (C) Serum was collected at day seven and analyzed for the
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above cytokines using a Milliplex Mouse Cytokine Kit. *p<0.05 in comparison to
infected WT controls. (D) Eggs/gram feces of WT mice adoptively transferred with
MDSCs or WT controls, both depleted of T cells (T dep) as described in Methods. (E)
Enumerated eggs/gram of feces of infected WT with AT of either CD11b+Ly6highLy6Clow
or CD11b+Ly6lowLy6Chigh population of MDSCs. (F) Enumerated eggs/gram feces of
mast cell deficient KitWsh/Wsh mice with and without MDSCs upon infection with 650 Nb
L3 worms. The data represents five mice per group.
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Figure 23. Mast cell/MDSC interaction augments cytokine production. BMMCs
were co-cultured with A10Tg MDSCs as described in Methods. Supernatants were
collected and analyzed for the production of (A) IL-6, (B) IL-13, (C) MIP-1α, and (D)
TNF-α. The data represent pooled spleens of at least three mice per group. *p<0.05 in
comparison to mast cells (MCs) alone.
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Figure 24. MC/MDSC interaction is required for MDSC-mediated immune
suppression.

Photographic representation (A) and quantification (B) of B16 lung

metastasis in control C57 and KitWsh/Wsh mice with and without the AT of MDSCs. The
data is representative of with at least five mice per group. *p<0.05 in comparison to WT
alone or KitWsh/Wsh with MDSCs.
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Figure 25. Tumor derived MDSCs promote Nb clearance. MDSCs isolated from LLC
injected mice and i.v. AT into wild type mice on days (-1,2,5,8) or controls, were
infected with 650L3Nb *P<0.05.
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Figure 26. MDSCs regain their effect in KitWsh/Wsh mice upon reconstitution with
MCs. KitWsh/Wsh mice were reconstituted with BMMC 20 weeks prior to experiment
(rWsh). Age matched unreconstituted KitWsh/Wsh mice (Wsh) mice were used as controls.
Mice were challenged with Nb in the presence or absence of MDSCs. Eggs per gram of
feces were determined on indicated days. ***P<0.0005 between rWsh and rWsh/M.
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Figure 27. MDSC-mediated parasite expulsion is abrogated in MC deficient Cpa3cre
Mcl-1fl/fl mice. WT and Cpa3cre Mcl-1fl/fl mice were infected with Nb with and without
the AT of MDSCs as described in Methods. Eggs per gram of feces were determined on
indicated days.
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Figure 28. MDSCs preferentially migrate to the liver in a MC-dependent manner.
(A) Wild type mice were adoptively transferred with PKH26GL labeled MDSCs 18hrs
post injection. PKH26GL staining was assessed on CD11b+Gr1+ cells in liver (Liv),
peripheral blood (PB), spleen (Spl) and bone marrow (BM). (B) KitWsh/Wsh mice (Wsh) or
wildtype (WT) were i.v. AT with PKH26GL labeled MDSCs on days (-1,2,5) and
infected (day 0) with 650L3 Nb. (C) Day 7 post Nb infection PKH26GL staining was
assessed on CD11b+Gr-1+ cells in the liver. (D) MDSCs were cultured in the top well of
8-micron transwell plates. B16 melanoma cells, BMMC cells or media alone were
placed in the bottom well. After 4hr incubation, cells were harvested from bottom wells
and CD11b+Gr-1+ MDSC migration was determined by flow cytometry.
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Figure 29. Hepatic MCs activate MDSCs and enhance cytokine production.
Cytokine analysis on supernatants of CD11b+Gr1+ MDSCs recovered from pooled livers
of WT Nb infected mice after adoptive transfer with MDSCs and cultured for 48hrs in
cRPMI. Pre-adoptive transfer MDSCs were used as control.
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Figure 30. MDSCs express HR1 and HR2. A. HR1 staining was determined on
CD11b+Ly6G+ (solid line), CD11b+Ly6C+ (dotted line) or CD11b- (grey) cells by FACS.
B. HR1 and HR2 presence was confirmed by western blotting.
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Figure 31. Histamine increases MDSC survival and proliferation. A. MDSCs were
purified and cultured in the presence of 100µM histamine. Cellular viability was
quantified using trypan blue exclusion over a 72 hr period. B. MDSCs were cultured with
5µM, 10µM or 100µM histamine (Invitrogen). All cell concentrations started with
50,000 cells/well in 96 well plates. To determine proliferation, cells were then labeled
with [H3]-thymidine. Plates were then harvested 24hrs later, using a Filtermate cell
harvester onto GFC plates, and read with a Topcount Plate Counter (Perkin Elmer,
Waltham, MA).
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Figure 32. Histamine receptor blockade abrogates MDSC proliferation. MDSCs
were pre-treated with CIM, CT or both and subsequently cultured with 100µM histamine
for 48 hours, and proliferation was determined using [H]3-thymidine incorporation.
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Figure 33. Both M-MDSCs and G-MDSCs are sensitive to the proliferative effects of
histamine. Ly6C+ or Ly6G+ MDSCs were cultured with 100µM histamine and
proliferation was determined using [H]3-thymidine incorporation.***P<0.0005. Data
represents Mean ± SEM.
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Figure 34. Histamine increases enzymatic activity of MDSCs. MDSCs were purified
as a heterogeneous group based on CD11b+Gr-1+ expression or as subsets based upon
Ly6G and Ly6C expression. They were subsequently cultured in the presence of 100 µM
histamine or in 04µm transwells with MCs. 24 hrs post co-culture, mRNA was isolated
and analyzed for expression of Arg1/18S (A,C) or iNOS/18S (B,D) by qPCR.
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Figure 35. HR antagonist blocks MDSC mediated Nb clearance. (A) Eggs per gram
of feces was determined over a time course in mice infected with 650L3 Nb, with or
without AT of MDSCs on days (-1,2,5,8,11) in the presence or absence of i.p. CT
treatment or CIM (D) treatment every other day.

B, E. Day 14 analysis of total

CD11b+Gr1+ MDSCs and (C,F) CD11b+Ly6C+ or CD11b+Ly6G+ populations in the liver
determined by flow cytometry from CT (B,C) or CIM (E,F) treated mice. *P<0.05,
***P<0.0005, NS=not significant. Data represents Mean ± SEM.
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Figure 36. HR antagonization inhibits MDSC mediated tumor progression. Mice
were challenged with B16 concomitant with MDSCs in the presence or absence of
cimetidine (CIM), an HR2 antagonist. Mice were subsequently sacrificed and their lungs
weighed for B16 colonization. *P<0.05
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Figure 37. Histamine differentially regulates STAT signaling in MDSC
subpopulations. The levels of pSTAT5 and pSTAT3, on Ly6C+ or Ly6G+ MDSC
populations, after 24 hours of culture with 100µM histamine was determined by western
blotting. Equal loading was confirmed with β-actin.
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Figure 38. Allergic Patients have increased circulating MDSCs. Allergic Patients
were defined as patients in active allergy, experiencing symptomology and compared to
non-allergic controls. Cells were isolated from peripheral blood and percent MDSCs and
subpopulations were determined by flow cytometry. A. Representative allergic patient
vs. control and (B) compiled.*P<0.05. Data represents Mean of 9 patients ± SEM.
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Figure 39. Human MDSCs have increased survival in the presence of histamine.
MDSCs sorted as HLA-DRlo/-CD11b+CD33+ and from peripheral blood of a stage I
breast cancer patient. Cells were stained for flow cytometry prior to culture and after 48
hours of culture with 100µM histamine or in media alone.
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Figure 40. An illustration of differential effects of Notch S2/S3 cleavage in
hematopoietic differentiation. In the presence of ligand, the Notch receptor undergoes
both S2 and S3 cleavage, resulting in two cleaved products and ultimately promoting T
cell development. In the absence of ligand or in the case of blocked S2 cleavage, the
Notch receptor remains intact and B cell development results. However, S2 cleavage
without S3 due to increased ADAM10 activity, results in myelopoiesis.
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Figure 41. Model of MDSC/MC interaction. MCs are required for MDSC activity.
MCs release mediators such as histamine that induce MDSC activation, proliferation and
Th2 cytokine production. This enhanced cytokine production culminates in Th2 skewed
immune responses that promotes allergy and parasitic clearance and diminish anti-tumor
responses.
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